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 The issues shrouding the use of embryonic stem cells and limitations of 
adult stem cells have directed research attention onto foetal stem cells.  This 
dissertation focuses on the human umbilical cord lining stem cells (UCSCs), 
investigating its potential for in vitro models in two broad directions on two 
populations of UCSCs, namely mesenchymal cells (UCLMCs) and epithelial 
cells (UCLECs) obtained from a patented explantation method. 
 
 The effects of varying concentrations of glucose and insulin on 
differentiation of the UCSCs to adipocyte-like cells (ALCs) were investigated in 
a 2
2 
factorial design format.  UCLMCs were subjected to adipogenic induction 
in different media cocktail, with insulin and glucose as the factors of interest.  It 
was observed that after 20 days of differentiation, UCLMCs in all adipogenic-
induced groups became irregular, cuboidal-shape cells that resemble adipocytes.  
In addition, Oil Red O staining showed accumulation of lipid droplets.  Up-
regulated gene expressions of PPARγ, an adipose specific nuclear hormone 
receptor, and adipsin, a protease synthesized predominantly in adipose tissues, 
were distinct indications of differentiation to mature adipocytes.  Further 
analysis of adipocytokines secretion by UCLMCs differentiated in low-glucose 
medium showed significant secretion of leptin and adiponectin, while those in 
high-glucose medium significantly secreted leptin only.  Insulin concentration 
affects leptin but not adiponectin secretion.  It was concluded that under 
different culture conditions, the UCLMCs can differentiate into ALCs that 
resemble adipocytes of either normal- or over-weight person.  Hence these 
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UCLMCs-derived ALCs have the potential to be used as in vitro model to study 
adipogenesis and obesity, and possibly as a drug discovery model for metabolic 
disorders. 
 
The differentiation of UCLECs into hepatocyte-like-cells (HLCs) and 
the potential of using these differentiated cells for in vitro drug 
biotransformation study platform were investigated.  UCLECs were subjected to 
28 days of hepatic differentiation, after which the fibroblastic shape of UCLECs 
changed to rotund polygonal resembling that of hepatocytes.  Negative protein 
expressions of α-foetal protein (AFP) and cytokeratin 19 (KRT19) coupled with 
upregulated albumin and KRT18 expressions signified commitment of UCLECs 
towards HLCs.  Maturity of the HLCs was illustrated via gene expressions of 
hepatocyte nuclear factor 4α (HNF4α), CYP1A2, CYP2D6 and CYP3A4.   
 
Further investigations on functionality of cytochrome P450 enzymes in 
HLCs was performed through incubation with drug substrates, followed by 
detection of respective hydroxylated metabolites by the UPLC/MS/MS.  
Functional CYP3A4 activity was identified in HLCs by means of 
hydroxytestosterone detection.  There were no CYP1A2 and CYP2C9 activities 
in HLCs, and it is postulated to be a consequence of cytochrome gene 
suppression and lack of essential coactivators to activate the enzymes.  
Nonetheless, the HLCs had expressed hepatic-specific markers and shown 
functional CYP3A4 activity that is essential of mature hepatocytes and therefore 
IX 
 
has the potential as an alternative cell source for in vitro drug metabolism 
studies, as well as study models of liver diseases.   
 
In conclusion, UCSCs are easily obtained, maintained and amendable to 
differentiation.  And therefore UCSCs is an excellent candidate for in vitro drug 
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CHAPTER 1: INTRODUCTION 
Since the first discovery of embryonic stem cells (ESCs) in human 
blastocytes by Bongso et al. in 1994 [1] and successful establishment of human 
stem cell lines by Thomson et al. in 1998 [2], stem cells have been in the 
limelight of scientific research in the recent decades.  At the mention of the term 
“stem cells”, great interest is aroused because these pluripotent cells have the 
intriguing ability to differentiate into different cell lineages across the three 
embryonic germ layers, ectoderm, mesoderm and endoderm [3, 4] and are able 
to regenerate themselves indefinitely.  Hence they are seen as the holy grail to 
cell-based therapy and regenerative medicine.           
 
1.1. Fascination with stem cells 
 
The exponential pursuit of stem cell research worldwide is evident from 
emerging reports of the potential applications of stem cells in therapy.  
Transplantation of human ESC-derived oligodendrocyte progenitor cells into rat 
spinal cord injuries at early time points was shown to promote improvement of 
motor function [5], and progenitor stem cells (PSCs) were thought to ameliorate 
myocardial infarction in rodent and porcine models [6, 7].  Review of 
mesenchymal stem cell (MSC) therapy for the treatment of chronic obstructive 
pulmonary disease [8] and generation of insulin-producing islet-like clusters 
from stem cells for replacement therapy in Type I diabetes seems promising [9, 
10].  Stem cells attract much attention due to its perpetual regenerative abilities 
and differentiation flexibility, giving hope that the dire shortage of tissues and 
organs for replacement of defective ones may be quenched. 
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Besides the direct application in regenerative medicine, the study of 
differentiation in stem cells provides a better insight to cell signalling and 
biochemical pathways during cellular development. This consequentially leads 
to better understanding of the causes of birth abnormality and disease 
progression, and hence launch the endeavours to rectify and prevent these 
genetic and physiological malfunctions.  In addition, stem cells have a part in 
pharmaceutical research, especially in the area of drug development and 
toxicology studies.  Both undifferentiated and differentiated stem cells can serve 
as a platform for in vitro screening of potential therapeutics, identification of 
drug targets, and pharmacological study models. 
 
1.2. What are stem cells? 
 
Stem cells are unspecialised cells that have the unique ability to renew 
themselves indefinitely through cell division and the potential to develop into 
any tissue- or organ- specific cells with specialised functions.   Depending on its 
source, stem cells are broadly categorised as ESCs or adult stem cells (ASCs) 
[11, 12].   
 
The human ESCs are derived from the inner cell mass of the blastocyst 
at Day 5 after fertilization, before implantation of the embryo (insert in Fig1-1).  
The isolated cells, known as blastomeres, are undifferentiated.  Under suitable in 
vitro conditions, these cells can be maintained as pluripotent ESCs and can give 
rise to any cells from all three embryonic germ layers (Fig.1-1).  Once 
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implantation is allowed to take place instead, the blastomeres rapidly lose their 




Fig. 1-1.  Differentiation of human tissues.  
Reproduced from Stem cells: Scientific Progress and Future Research  




The ASCs are non-embryonic stem cells found in our bodies, starting 
from the time of foetal development.  Therefore the term “ASCs” refers not only 
to stem cells found in the adult bodies per se, but also includes foetal stem cells 
(FSCs) from the umbilical cord, the cord blood and the placenta.   Other terms 
“somatic stem cells”, “tissue-specific stem cells” and “progenitor stem cells” 
have also been used to describe these differentiation-capable non-embryonic 
stem cells.  To date, ASC niches have been identified in many different parts of 
the body, such as the bone marrow [15-18], adipose tissues [19], trabecular bone 
[20], and dental pulp [21].  These progenitor cells are less specialised than the 
surrounding cells where they are found, regenerating to replace the surrounding 
somatic cells lost daily due to senescence or injuries.  However, this self-
renewal ability will decline over time.  Depending on the origin of its niche, the 
ASC potency ranges from multi-, tri-, bi- to unipotent.  Based on the hierarchy 
of cell plasticity, cell differentiation potency wanes in the order of: totipotent, 
pluripotent, multipotent and unipotent [12].  Therefore ASCs are able to 
differentiate albeit to a limited extent as compared to pluripotent ESCs (Fig. 1-
2).  Nonetheless, it has been reported that under the influence of different 
growth factors in culture medium, ASCs are able to transdifferentiate across 








Fig. 1-2.  Developmental stages and potency of cells. 
ASCs: adult stem cells, ESCs: embryonic stem cells, FSCs: foetal stem cells, ICM: inner cell 
mass, PSCs: progenitor stem cells, UCB: umbilical cord blood.  At the top of the cell 
plasticity hierarchy are totipotent zygote cells that have the ability to 
differentiate into all cell types including the extra embryonic tissues, the embryo 
and all postembryonic tissues and organs.  Hence if the zygote is allowed to 
develop further into an embryo for implantation and differentiation, an entire 
organism is generated.  Isolated blastomeres from ICM give rise to pluripotent 
ESCs in vitro.  Through asymmetrical cell division, ESCs, FSCs, ASCs and 
PSCs give rise to two different daughter cells; one is a copy of the original 
pluripotent/multipotent stem cell, and the other is a less potent daughter cell 
programmed to differentiate further into other PSCs type with more restricted 
potential or somatic cells.  The FSCs are found to exhibit features of 
pluripotency and multipotency, therefore they are at an intermediate 













1.3. Embryonic Stem Cells Vs Somatic Stem Cells 
 
ESCs are no doubt versatile to manipulation.  By adjusting in vitro 
conditions, the desired specialized cells can be generated.  However this 
pluripotency becomes a double-edged sword when transplanted ESCs show the 
tendency to form teratomas [2].  Secondly, the inherent problem of 
transplantation, which is immunogenicity, needs to be addressed.  Although 
there are strategies to prevent transplant rejection through administration of 
immunosuppressive drugs, induction of immunological tolerance, and genetic 
engineering of cells, the major drawbacks and accompanying complications 
such as graft-versus-host disease and increase susceptibility to opportunistic 
infections pose challenges [25].  It has been illustrated that ESCs and ESC-
differentiated cells stimulate immune response after transplantation [26].  Most 
importantly, the ethical concerns and controversies that shroud the usage of 
ESCs have been a major road block to its research and clinical applications.  
Since the discovery of human ESCs more than 10 years ago, the California-
based company, Geron, received US FDA approval to begin the first human 
clinical trial of cells derived from human ESCs only in January 2009.   Apart 
from the financial and time investment in the necessary in-depth scientific 
research, it will take a greater effort to convince the general public and pro-life 
activist groups to accept the use of human ESCs for large scale research and 
clinical applications.   
 
ASCs have an edge over the more versatile ESCs in that bioethical 
controversies are avoided.  Hence further development of ASCs from bench top 
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to clinical applications should be generally acceptable.  This paves the way for 
easy access to the cell source, and therefore hastens cell-based regenerative 
medicine research.  As such, these multipotent progenitor cells are an attractive 
alternative cell source for regenerative medicine.    
 
  Although they are at a lower level of plasticity compared to ESCs, 
ASCs are sufficiently versatile for differentiation into most cell lineages [27].   
It was shown that undifferentiated and differentiated mesenchymal ASCs do not 
elicit alloreactive lymphocyte responses and they support unrelated donor 
hematopoietic stem cells by suppressing T-cell activation thereby reducing 
immunological complications after transplantation [28-30].  In addition to their 
immune modulating properties, MSCs have been successfully used as targeting 
vehicles in gene therapy with various therapeutic molecules [31-34].  Wound 
healing quality was also shown to be improved with MSC autografts [35-37]. 
 
To date, the most established source of ASCs that is clinically used is the 
bone marrow.  Two populations of ASCs have been identified, namely bone 
marrow mesenchymal stem cells (BM-MSCs) and the bone marrow 
hematopoietic stem cells (BM-HSCs) [16].  The MSCs can differentiate into 
somatic cells such as adipocytes, osteocytes and chondrocytes, while the HSCs 
are blood-forming stem cells that can differentiate to form all blood cells.  
Hematopoietic transplantation using BM-HSCs is the main stream of cell-based 
therapy. However, bone marrow derived cells are losing their appeal as cell 
quality may deteriorate in relation to age.  Choumerianou and co-workers 
compared the stemness characteristics of bone marrow derived MSCs of 
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children and adults [17].  They found that compared to MSCs from adult bone 
marrow, those from children bone marrows have high proliferative potential, 
fast growth rate, more clonogenic and long telomeres, which are properties 
important for transplantation setting.  Further in the rodent model, Stolzing and 
Scutt illustrated that the age of the animal has an impact on the functional 
capacity of the bone marrow mesenchymal progenitor cells [38].  There was a 
reduced ability to maintain mesenchymal tissue homoeostasis in aged mammals 
as a result of decline in progenitor cell numbers and functionality due to the 
accumulation of oxidative damage.  The problem of declining capacity of bone 
marrow-derived MSCs due to the age of the donors translates to difficulty in 
finding enough donors to obtain sufficient progenitor cells of high quality.  
Furthermore, the collection of PSCs from the bone marrow involves invasive 
surgical procedures, causing mental and physical stress to donors, as well as risk 
of postsurgical infections.   
 
Besides the declining quality with age, another major disadvantage of 
most ASC sources is the difficulty to obtain the progenitor cells in sufficient 
quantity for large scale research and clinical applications.  Although many 
progenitor cell niches have been identified in various parts of the body [19-21, 
39], there is limited access to these cells.  To rely on spontaneous donation of 
tissues from elective surgeries such as liposuction and as a result of death to 
sustain scientific research and wide spread clinical usage are not feasible options.  
It is proposed that the ideal cell source should possess the following attributes: 
1. Ease of collection 
2. Reliable  supply 
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3. Sufficient quantity for scale-up  
4. Consistent cell qualities and functions 
5. Minimum bioethics dilemma and legislation tussle 
 
 
1.4. Alternative pluripotent stem cells 
Scientists have found many sources of stem cells, and also discovered 
strategies to re-programme somatic cells to become pluripotent cells.  The birth 
of Dolly, the famous sheep “conceived” through somatic cell nuclear transfer 
[40] in 1997, triggered a tremendous wave of interest in regenerative medicine 
by the public and life science community.   Alternative methods of deriving 
pluripotent cells from non-pluripotent cells have since evolved.  The latest 
accomplishment is induced pluripotent stem cells (iPSCs), which uses retroviral 
expression vector to introduce four important stem cell factors into somatic cells 
to reprogram them to behave like embryonic stem cells [41, 42].  Whenever the 
use of viral transgene delivery system is involved, it is always bundled with the 
concern of incomplete silencing or unwanted activation of the viral transgenes, 
and most importantly the risk of random gene insertion leading to mutagenesis.  
Modifications have been made to the method of introducing the four crucial 
inducing factors, such as via plasmid based transfection or using recombinant 
protein.  However, these methods are generally laborious and have very low 
efficiency in producing iPSCs.  Moreover, Miura and colleagues demonstrated 
that differentiated iPSCs have varying propensity to form teratomas in mice 
depending on the origin of the somatic cells [43].  Therefore another 
fundamental question in reprogramming somatic cells is the source of these cells.   
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The tenet that is driving the acquisition of pluripotent cells is the promise that 
these cells hold in the field of regenerative medicine, the platform for 
scrutinising and understanding cellular development, pathology, and interactions 
with drugs.  However, the umbilical cord and placenta have been found to 
possess unlimited supply of multipotent progenitor cells that could potentially 
fulfil these roles.  Hence there is less necessity to invest time and resources to 
manipulate and reverse the fate of somatic cells for the same purpose. 
 
1.5. Foetal Stem cells: Youth is an asset 
As age is an issue with regards to cell quality, regenerative medicine 
research interest is shifted from the adult to a younger PSCs source: foetal stem 
cells (FSCs).  Once discarded as biowaste after deliveries, the placenta and 
umbilical cord are now recognised as an invaluable source of unlimited supply 
of PSCs.  Multipotent cells have been isolated from foetal and extra-embryonic 
cell sources, including placenta [44-46], amniotic fluid [47-50], cord blood [51-
53], the Wharton’s Jelly [54-57], and also amniotic membrane [58].  With 
regards to proliferation rates and plasticity features, these PSCs from foetal 
origin represent intermediate between ESCs and PSCs from adult tissues and 
organs [23, 24] (Fig. 1-2).  The FSCs are shown to have pluripotent markers 
found in ESCs, and proliferate faster than adult PSCs.  In addition, these cell 
sources are usually discarded following birth and their collection causes no 
harm to any individual.  These features are desired attributes of a cell source.  
Nonetheless, each subtype of foetal cell source has its limitations that need to be 
reviewed and fine-tuned. 
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 The placenta is a vital organ that connects the developing foetus to his 
mother, supplying nutrients and gaseous exchange and eliminating waste via the 
mother’s blood supply.  Originating from the trophoblast of implanted 
blastocysts, blood vessels branch out from the developing embryo to form 
villous tree structures and attach to the maternal uterine wall, subsequently 
develop into the placenta.  MSCs have been successfully isolated from the 
placenta, thus the organ seems to be a promising alternative cell source to the 
conventional BM-MSCs [44-46].  However, the complex intertwining structure 
of the circulatory system between the foetus and mother makes harvesting of 
homogenous placenta-derived progenitor cells of foetal origin challenging.  To 
avoid cross contamination of foetal and maternal cells, the placenta needs to be 
collected whole via caesarean section by skilful dissection of the decidua tissue 
from the uterine wall (Fig. 1-3). 
 
Questionable processing methods to yield MSCs of either maternal or 
foetal origin were reported.  Barlow and co-workers subjected placental tissues, 
including amnion, chorion and desidua basalis, to enzyme digestion and 
centrifugation to obtain mononuclear cells for plating [44].  Their data purports 
the MSCs obtained were exclusively of maternal origin.  Supporting their data is 
an investigation by Wulf’s group, but they removed the amniotic membrane 
before enzyme digestion [45].  On the other hand, In’t Anker and team found 
that the placenta can be a source of both foetal and maternal MSCs, where the 
amnion is a source of foetal MSCs, while decidua basalis and decidua parietalis 
are sources for maternal MSCs [46].  Origin of the placenta-derived MSCs 
remains to be investigated.  Moreover, the reliance on caesarean section for 
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harvesting of a whole placenta is debatable as comparison studies showed 
higher maternal morbidity in elective caesarean section including febrile 
morbidity, wound infections in the postpartum period as compared to planned 
vaginal delivery in the low-risk obstetric population [59, 60]. 
 
Fig. 1-3.  Foetal stem cells niches.   
Sagittal view of the womb and basic tissues surrounding the developing foetus 
at first trimester gestation.  (A) Intertwining circulatory system at maternal-
foetal interface of placenta.  (B) The umbilical cord containing two umbilical 
arteries and an umbilical vein usually attaches near the centre of the placenta, 
facilitating nutrients, waste and gaseous exchange between the mother and 
foetus.  The Wharton’s Jelly cushions the blood vessels against pressure.  
(Illustration reconstructed from references [61, 62] ) 
 
Amniotic fluid was found to be a novel source of multipotent progenitor 
cells that express ESCs and ASCs markers, and are able to differentiate into cell 
types representing each embryonic germ layer such as adipocytes, osteocytes, 
hepatocytes and neuronal cells [47-50].  However, the setting up of a bank of 
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amniotic fluid ready for use brings about the tenacious question of cell supply.  
The amniotic fluid samples reported are obtained from amniocentesis, which 
carries risk of miscarriage, needle injury to the foetus and other post-procedure 
complications to the mother.  Hence unless there is a serious necessity for 
prenatal diagnosis of possible genetic defects or to determine maturity of the 
foetal lungs for early delivery, amniocentesis procedure is not the norm during 
routine antenatal checks.  To depend on the group of pregnant women who 
require amniocentesis for supply of amniotic fluid samples will only provide 
sufficient cells for laboratory studies. 
 
In recent times many cord blood banks have been established, especially 
in the private sector.  Umbilical cord blood (UCB) is found to be a good 
alternative source of HSCs to bone marrow [63].  As a result of successful 
clinical applications of UCB to treat hematopoietic disorders [64-66], many 
parents rush to bank in the UCB of their newborns as an insurance against any 
possible needs in the future.  Unfortunately, the potential of UCB as an 
alternative MSCs source for clinical applications remains controversial.  
Mareschi’s team failed to isolate MSCs from UCB samples of full-term babies 
[18], while Erices and co-workers reported low yield of MSC-like cells [51].  
Perdikogianni’s group reported that only 25% of the cultured UCB samples 
formed an adherent layer of MSC-like cells under optimal culture conditions.  
Of the five optimal conditions identified, a large initial sample volume of 40 ml 
or more is needed [67].  And in comparison to bone marrow, a much higher 
initial concentration of mononuclear cells is needed to isolate MSC from UCB.  
Bieback and his researchers also reported the isolation yield to be about 60%, 
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depending on critical parameters such as time from collection to isolation, and 
net volume of the UCB [68].  As the clinical use of UCB emerges, standardised 
optimal collection and culturing conditions need to be further determined before 
UCB may substitute for the traditional bone marrow stem cells.    
 
1.6. Umbilical cord progenitor cells 
In contrast to UCB, umbilical cords have been shown to be a richer 
source of non-hematopoietic progenitor cells.  A comparison of efficiency in 
obtaining MSCs from paired UCB and umbilical cord samples from the same 
donor resulted in only 1 of the 10 UCB samples generating MSCs, while large 
amounts of MSCs were obtained from all umbilical cord samples [69].  It was 
shown that multipotent progenitor cells can be isolated from the umbilical cord 
in abundance.  These cells have hematopoiesis-supportive function and the 
ability to differentiate in similar manner as BM-MSCs into osteogenic, 
chondrogenic, adipogenic and myogenic cells in vitro [70, 71].   
 
Baksh’s team compared the proliferative and multilineage differentiation 
potential of human MSCs derived from umbilical cord and bone marrow [72].  It 
was found that umbilical cord derived MSCs (UC-MSCs) were similar in 
characteristics to BM-MSCs and they expressed Wnt signaling pathway genes 
that have been implicated in regulation of MSCs.  In addition, UC-MSCs 
showed a higher proliferative potential and expressed higher levels of CD146, a 
MSC marker, relative to bone marrow. 
15 
 
Umbilical cords are attractive cell source because they are easily 
available without undue inconvenience to the donors and less ethical hassle as 
there is neither mortality nor risk of morbidity involved.  There is an irrefutable 
unlimited supply of umbilical cord lining cells (UCLCs) as the birth of every 
baby is accompanied by an umbilical cord, and it can be collected regardless of 
vaginal birth or caesarean section.  Furthermore, umbilical cords are collected 
from full-term and healthy babies.  Therefore all the UCLCs are consistently 
young and healthy at only about 10 months old since embryogenesis.  
Investigations using microarray had revealed that transcript involved in cell 
proliferation, chromatin regulation, DNA repair and developmental genes were 
more abundantly expressed in foetal MSC as compared to its adult counterpart.  
Foetal MSCs also expressed fewer transcripts involved in terminal tissue 
differentiation, indicating that it is less lineage-committed and more 
proliferative than adult MSCs [24, 73].  These two characteristics render foetal 
MSCs more flexible to manipulations so as to meet desired needs of clinical or 
bench work applications. 
 
The umbilical cord is made up of two umbilical arteries, one umbilical 
vein and the allantoic duct surrounded by the Wharton’s Jelly, which is enclosed 
by the amniotic membrane (Fig. 1-3).  It has been reported that PSCs can 
isolated from the Wharton’s Jelly [50-53] and amniotic membrane [58].  To date, 
the conventional methods employed to isolate the multipotent cells from the 
umbilical cord subjects the entire cord tissues to a series of enzymatic digestion 
and centrifugation steps after removal of the blood vessels.  This is likely to 
produce heterogeneous cell populations consisting of MSCs and other somatic 
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cells.  The heterogenic cell populations obtained will be trickier to manage as it 
is uncertain how much residual somatic cells still reside in that particular sample, 
depending on the efficiency of the enzyme treatment and further downstream 
processing steps.  Subsequently the effect of these other residual cell types on 
differentiation of the intended progenitor cells leads to yet another unknown.   
 
An overview of the various stem cell sources is summarised in Table 1-1.  
A comparison of the main features of each source showed that amniotic 
membrane is the most ideal cell source.  Nonetheless, the method of generating 
a consistent cell supply from the amniotic membrane needs to be addressed.  
Continuing from the umbilical cord, the amniotic membrane also lines the foetal 
side of the placenta.  In the study by Alviano and co-workers, the amniotic 
membrane was separated from the placenta before subsequent processing [58].  
This separation procedure is possible only if the whole placenta is collected 
during delivery, and requires meticulous techniques to avoid cross 
contamination between the amniotic membrane and placenta tissues.  Hence it 
raises the question of consistency in the quality of the cells obtained.  In 
addition, tedious processing protocols will pose challenges for scale-up 




















     
 Proposed basic attributes  of 
stem cell sources  





 - -   
 Pluripotent:: amenable to 
differentiation 
 Genetic & epigenetic changes 
over time 
 Teratomas formation 
 Low cloning efficiency 
 Immunogenic 
 Derived from unused embryos 






 Pluripotent/multipotent characteristics: amenable to differentiation 
 High cloning efficiency 





     
 Ambiguity of foetal or maternal 
PSCs 
 Collection via caesarean needs 
skilful dissection 
 Collection via vaginal birth may 






[47-50]      
 Mixture of different cell types 
require proper selection for 
PSCs 
 Only ≈1% of cells in samples 






[18, 51, 52]      
 Large initial sample volume 
required 
 Adherence to stringent 
collection & culture conditions 
needed 






     
 PSCs isolation involves 
trypsinizing umbilical cord; 
ambiguity of PSCs originating 







    (?) 
 Present isolation methods 
tedious and may generate 




















 More restricted multipotency capacity 
 Variable cloning efficiency base on cell origin 
 Unreliable cell supply, depending on elective surgeries or volunteer donors 
 Many niches have been identified, 2 representatives which are more common are selected 




[17, 18]      
 Declining PSCs number & 
functionality in relation to age of 
donor 








     
 Low proliferative ability 
 Unpredictable variability among 
donors & anatomical sites 
 
(: No,  : Yes,     : Not applicable,  : to be addressed )   
Conventional isolation methods of stem cells from amniotic membrane produce 
cells of debatable qualities and consistency.  This can be easily overcome and 
will be addressed in section 1.6.  
 
1.7. Explantation - an improved isolation method for UCSCs 
Generally, primary cultures can be obtained from tissues by enzymatic 
disaggregation, mechanical disaggregation or fine dissection to explant size.  
Primary-explant technique originated in the early 1900s for initiating a tissue 
culture.  The original method was performed by embedding a fragment of tissue 
in blood plasma, which has been replaced by the simplified method of using 
growth medium with serum [79].  Recently, Lim and Phan isolated stem cells 
from the human umbilical cord based on the basics of primary-explant technique 
[80].  The use of explant method in isolation of cells from the umbilical cords 
have not been reported to date as most research groups would use the 




In the patented isolation protocol by Lim and Phan [80], the amniotic 
membrane is separated from other components of the umbilical cord, followed 
by repetitive tissue explantation and subsequent culture in proprietary growth 
media that supports the proliferation of MSCs or epithelial stem cells (EpiSCs).  
This method of cell cultivation without the use of enzyme digestion of the entire 
umbilical cord is more efficient and much easier to perform, as well as less 
handling stress for the cells.  Additionally, high quantity and quality cells are 
assured from low passage number.   Reported isolation of stem cells from the 
umbilical cords by other research groups thus far are restricted to only MSCs 
[54-57].  On the contrary, the explantation method with use of proprietary media 
cocktail yields two separate populations of multipotent MSCs and EpiSCs for 
specific studies and applications, hence widens the horizon for regenerative 
medicine. 
 
Isolation and characterisation of MSCs from the amniotic membrane of 
the umbilical cord using the above explantation technique illustrated that the 
cells have significant expression of typical stem cell-specific markers such as 
SSEA-4, Oct-4 and Nanog, while typical ESC-specific markers were not 
expressed.  Further demonstration of distinction between the amniotic 
membrane derived-MSCs and ESC-MSCs is the absence of cell growth in soft 
agar, indicating non-tumorigenicity in vitro [81].  In addition, a comparison 
between umbilical cord lining mesenchymal stem cells (UCLMCs) and adult 
BM-MSCs showed that UCLMCs had a stronger immunosuppressive potential 




The isolated umbilical cord lining epithelial cells (UCLECs) have been 
characterized and found to express non-classical forms of major 
histocompatibility complex (MHC), HLA-G and HLA-E, at levels similar to 
those observed in human trophoblasts [83].  During the course of pregnancy, the 
foetus is considered an allograft to the mother because the paternal MHC 
antigens expressed by the foetus is regarded as foreign antigen, and yet the 
foetus is not rejected by the mother’s immune system.  HLA-G had been 
reviewed to play a crucial role in maternal-foetal immune tolerance [84, 85].  
The highly proliferative UCLECs with significant clonogenic ability were 
shown to express mucin 1, ESC markers Oct-4, Nanog, SSEA-4, REX1 and 
SOX2, as well as MSC marker CD166 [71]. 
 
Together with the above review of various ASCs sources and reported 
favourable characteristics of progenitor cells obtained from explantation method, 
the umbilical cord lining membrane appears to be the best choice for FSCs as it 
meets the ideal attributes proposed earlier.  Among the many diseases and 
healthcare issues that need to be addressed, obesity and liver diseases pose the 
most significant impact on healthcare cost.  In the following chapters this 
research will delve deeper into the potential of these umbilical cord lining 
derived stem cells to serve as in vitro study models for adipogenesis and drug 






CHAPTER 2: HYPOTHESIS AND OBJECTIVES 
Our objective is to develop umbilical cord lining derived-cells into in 
vitro models for clinical and laboratory research in drugs and diseases.  
Investigations will be carried out in two broad directions: 
1) From the umbilical cord lining mesenchymal cells (UCLMCs): 
It is hypothesised that adipocyte-like cells (ALCs) differentiated from 
the UCLMCs can be utilised as an in vitro obesity study model.  By 
manipulating glucose and insulin concentrations, ALCs can be induced to mimic 
adipocytes of normal-weight or over-weight individuals. 
 
2) From the umbilical cord lining epithelial cells (UCLECs): 
It is hypothesised that the UCLECs can differentiate to give hepatocyte-
like cells (HLCs) that can function like hepatocytes and has the potential to 





CHAPTER 3: DIFFERENTIATION OF UCLMCS TO 
ADIPOCYTE-LIKE CELLS 
3.1. Introduction 
3.1.1. The cost of being BIG 
Obesity is one of the major healthcare burdens of developing and 
developed nations.  Prevalence of obesity is worrying because it not only affects 
physical appearance and hence self-esteem, the disease is significantly 
associated with diabetes, high blood pressure, high cholesterol, asthma, arthritis, 
and poor health status [86].  Pharmacoeconomic projections indicate rising 
healthcare expenditure due to increasing obesity and related comorbidities [87-
89].  Data from the Australian Diabetes, Obesity and Lifestyle study revealed 
that in 2005, the annual total direct cost due to overweight and obesity was 
AUD10.7 billion more than the cost for normal-weight individuals [90].  A 
quantitative systematic review of direct medical cost of overweight and obesity 
in the USA reported that for 2008, per-person direct medical cost of overweight 
was USD266 and of obesity was USD1723, putting the aggregate national cost 
of the two diseases combined at USD113.9 billion, which amounts to 
approximately 5% to 10% of US healthcare spending [91].  In Singapore, 
disease burden statistics from the Ministry of Health showed obesity ranked 
fourth among the top five diseases in adults aged 18 to 69 years, and obesity-
associated diseases: hypertension, diabetes and high total cholesterol ranked the 
top 3 spots, accordingly [92].  The alarming cost of obesity warrants a deeper 




3.1.2. Adipogenesis and Adipocytes 
Adipocytes comprise approximately 35% to 70% of the adipose mass in 
adults.  The lipid-laden cells are found in adipose tissue composed of not only 
adipocytes but also other cell types, which include macrophages, fibroblasts, 
pericytes, blood cells, endothelial cells, and adipose precursor cells among 
others.  Adipose tissues function as a store of reserve energy and play a vital 
role as secretory organ in regulation of immunological responses, reproduction, 
vascular diseases, and appetite regulation.  Adipogenesis begins early during 
gestation period and the adipose tissue expansion progresses rapidly after birth 
due to increase in the size and number of adipocytes.  Peroxisome proliferator-
activated receptor-γ (PPARγ) had been identified as one of the transcription 
factors critical for adipocyte differentiation.  It is induced before transcriptional 
activation of most adipocyte genes.  When there is excessive food intake, 
existing adipocytes enlarge to accommodate the excess energy.  This 
hypertrophic process can result in accumulation of excess lipids by adipocytes 
up to four times their normal size. If the positive energy balance situation persist 
until existing adipocytes reach their critical size, an increase in total adipocyte 
numbers ensue and consequently lead to obesity [93-95].  Studies have shown 
an upregulation of adipsin, a protease synthesized predominantly in adipose 
tissues, with increased body mass [96, 97]. 
 
Undoubtedly adipogenesis and obesity have been extensively studied in 
animal models or cell lines such as the ob/ob or tubby mouse model and the 
3T3-L1 or   F442A murine cell lines.  Nonetheless there are genetic differences 
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between animal and human, which may be crucial to the study of obesity in 
human.  On the other hand, the use of human pre-adipocytes from adipose tissue 
is not ideal.  These cells, already committed to adipogenic lineages, have 
reduced proliferative ability, and unpredictable variability based on different 
donors and anatomical sites [78].  The use of human bone marrow mesenchymal 
progenitor cells to study adipogenesis is well underway.  These precursor cell 
types allow insights into biochemical pathways leading to adiposity and 
identification of crucial signalling molecules or pathways that may control the 
development of obesity and thus the discovery of therapeutic drugs for the 
disease [98, 99].   
 
Insulin regulates glucose uptake and causes fatty acid transport, protein 
translocation and enhanced fatty acid uptake in adipocytes [100]. The 
requirement of insulin-like growth factor-I or pharmacological concentrations of 
insulin in adipogenesis has been demonstrated and well-recognised [93, 101-
103].  From the review of published literature, it was noted that basal culture 
media of different insulin and glucose concentrations have been used to induce 
adipogenesis progenitor cells from several sources, such as insulin 
concentrations as low as 0.3 µg/ml (50 nM) to 57.3 g/ml (10 M) and 
commercially available media of either low-glucose or high-glucose content 
(Table 3-1).   
 
In all these studies, adipogenesis experiments were carried out to 
illustrate the multipotency of MSCs, and the differentiated ALCs were indicated 
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by means of positive Oil Red O stain for lipid droplets.  However, none of them 
compared the effects of varying concentrations of insulin and glucose on the 
phenotype of ALCs obtained from the differentiation.  Our study investigated 
the influence of glucose and insulin concentrations on in vitro adipogenesis, and 
hence explored the potential of the UCLMCs for in vitro research in 
adipogenesis and obesity.  As leptin and adiponectin are two adipocytokines 
closely associated with adipocytes, their secretions by the ALCs were examined 




Table 3-1. Insulin and glucose concentrations of in vitro adipogenesis 
models. 








 57.33 [19] 















 7.50 [104] 
Adipose tissue DMEM/F12
@





+   Glucose content not clearly stated.   
#  Choice of medium not clearly stated. Assumed it is the same as the medium used during 
clonal expansion. 
@ Glucose content not clearly stated. Assuming no manipulation to media from supplier, 
glucose content taken to be 3.15g/L (based on Invitrogen’s formulation).  
 
All cell sources were of human origin.  This mini review focuses only on the 
insulin and glucose concentrations. Hence variations in adipogenesis protocols 
and concentrations of other adipogenic supplements used are not considered. 
 
3.2. Materials and methods 
3.2.1. Materials 
Low glucose Dulbecco’s Modified Eagle Medium (LG-DMEM), high 
glucose Dulbecco’s Modified Eagle Medium (HG-DMEM), Ham-F12 medium, 
CMRL-1066 medium and antibiotic-antimycotic solution were from Gibco™ 
(Carlsbad, CA, USA).  Dulbecco’s Modified Eagle Medium (DMEM) was 
purchased from National University Medical Institute, Singapore, and fetal 
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bovine serum (FBS) was from Hyclone (Waltham, MA, USA).  Transforming 
growth factor beta-1 (TGF-1), basic fibroblast growth factor (bFGF), insulin-
like growth factor (IGF) and platelet-derived growth factor (PDGF) were from 
R&D Systems, Inc (Minneapolis, MN, USA).  UCLMCs from three different 
umbilical cords were randomly selected from the specimen bank of 





(Hilden, Germany), while the DNase I was from Fermentas 
(Burlington, Ontario, Canada).  Oligonucleotide and 10x TAE buffer was from 
1
st
 Base Pte Ltd, Singapore.  All primers, ReactionReady™ Human GAPD 
internal normaliser, and ReactionReady™ Hotstart “Sweet” PCR Master mix 
were from SABiosciences™ (Frederick, MD, USA).  The SuperScript™ III 
Reverse Transcriptase and Ultrapure agarose powder were from Invitrogen™ 
(Carlsbad, CA, USA).  Gel Red™ was from Biotium, Inc (Hayward, CA, USA).  
Loading dye and 100bp DNA ladder were from Promega (Madison, WI, USA).   
Leptin and adiponectin ELISA kits were from RayBiotech, Inc. (Norcross, GA, 
USA), and Amicon
 
Ultra-15 10K centrifugal filter device was from 
Millipore™ (Billerica, MA, USA).  Pierce bovine serum albumin 2 mg/ml was 
purchased from Thermo Scientific (Waltham, MA, USA) and protein assay dye 
reagent concentrate was purchased from Bio-Rad (Hercules, CA, USA).  
Besides -mercaptoethanol and formaldehyde from ICN Biomedical, Inc. 
(Aurora, OH, USA) and ethanol from Fisher Scientific (Hanover Park, IL, USA), 
all other chemical reagents were purchased from Sigma-Aldrich (St.Louis, MO, 





3.2.2.1. Source of UCLMCs 
Throughout this project, human umbilical cords were collected by 
CellResearch Corporation, Singapore with the informed consent of the mothers 
after normal deliveries of healthy, full-term babies.  All cells were isolated by 
personnel of CellResearch Corporation, Singapore as previously described [80].   
Briefly, the Wharton’s jelly and blood vessels were separated from the umbilical 
cord amniotic membrane by dissection.  The isolated amniotic membrane was 
cut into small pieces and explanted onto tissue culture dishes.  For expansion of 
UCLMCs, proprietary growth medium was a mixture of DMEM, Ham-F12 and 
CMRL-1066 media supplemented with human albumin, TGF-1, PDGF, bFGF, 
IGF and 2% FBS.  The UCLMCs used in the experiment were at either passage 
3 or 4.  UCLMCs from three different umbilical cords were randomly selected 
from the specimen bank of CellResearch Corporation, Singapore.  Each set of 




Cells were plated at a density of 5000 cells/cm
2
 and cultured at 37
o
C in 
an atmosphere of 95% air and 5% carbon dioxide.  Upon reaching confluency at 
passage 3 or 4, the UCLMCs were divided into different treatment groups as 
shown in Table 3-2.  The groups of cells were incubated in the respective basal 
medium and insulin concentrations in the presence of adipogenesis induction 
agents (0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 200 µM indomethacin 
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and 1 µM dexamethasone) for 6 days (Table 3-2).  This was followed by 
maintenance medium containing only the respective basal medium and insulin 
concentrations for 2 days (Fig. 3-1).   After two induction-maintenance cycles, 
the cells were incubated in induction medium for another 4 days.  Control group 
was incubated in DMEM throughout the 20 days of experiment. All five groups 
were supplemented with 10% v/v FBS and 1% v/v antibiotics-antimycotic 
solution.  The media were refreshed every 2 to 3 days.  
 
Table 3-2. Basal media, glucose and insulin concentrations used for 
treatment groups. 
DMEM: Dulbecco’s Modified Eagle Mediun, LG-DMEM: low glucose Dulbecco’s Modified 
Eagle Medium (1 g/L D-glucose), HG-DMEM: high glucose Dulbecco’s Modified Eagle 
Medium (4.5 g/L D-glucose).  The selection of basal medium and insulin 
concentration for each treatment group was maintained as above throughout the 
20 days of experiment.  Medium for all groups were supplemented with 10% v/v 
FBS and 1% v/v antibiotics-antimycotic.  
  
Group 







N (Control) DMEM 4.5 0  
LGLI LG-DMEM 1.0 10  
LGHI LG-DMEM 1.0 50  
HGLI HG-DMEM 4.5 10  
HGHI HG-DMEM 4.5 50  
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Induction Maintenance Induction Maintenance Induction 
     
 
Fig. 3-1. Adipogenesis schedule. 
The four treatment groups were subjected to adipogenic induction in accordance 
to this schedule.  Control group was maintained in DMEM throughout the 20 
days.  Induction media for all other groups contained adipogenic agents: 0.5 mM 
IBMX, 200 µM indomethacin and 1 µM dexamethasone.  Maintenance media 
contained all respective components except the three adipogenic agents. 
 
3.2.2.3. Oil Red O staining 
Oil Red O staining was performed on Days 3, 10 and 20 of 
differentiation to determine the accumulation of lipid droplets over time.   
Briefly, the cells were fixed in 4% v/v paraformaldehyde at room temperature 
for 1 hr, and followed by staining with freshly prepared Oil Red O (in 60% v/v 
isopropanol) solution for 30 mins.  Excess stain was removed by washing with 
70% v/v ethanol.  Hematoxylin was used as nuclear counterstain.   Cell staining 
was visualised under light microscopy. 
 
3.2.2.4. Reverse transcription-PCR (RT-PCR) 
Total RNA was extracted using the kit in accordance to manufacturer’s 
instruction.  The amount of RNA obtained was measured using NanoDrop ND-
1000 spectrometer (Wilmington, DE, USA).  Prior to synthesis of first strand 
complementary DNA (cDNA), the RNA samples were treated with DNase I to 
eliminate genomic DNA contamination.  Primers specific for peroxisome 
proliferator-activated receptor gamma (PPAR) and adipsin were used to 
synthesize cDNA from 1 µg of total RNA.  The reaction mixture was incubated 





C for 10 mins to activate the DNA polymerase, followed by 
thermal cycling at 95
o
C, 15 sec; 55
o
C, 30 sec; 72
o
C, 30 sec for 35 cycles.  An 
additional 10 minutes of incubation at 72
o
C was carried out after completion of 
the last cycle.  The PCR end products were electrophoresed on 2% w/v agarose 
gel containing Gel Red in 1x TAE buffer and visualised under UV light.  RT-
PCR was performed in triplicates for each patient sample.  Band intensity 
signals of the PCR products were quantified using Gel-Pro Analyzer 4.5.  Band 
intensities were calculated as the gene of interest-to-GAPD signal intensity ratio.  
The ratios obtained were analysed using one-way ANOVA with Tukey’s HSD 
post hoc comparisons.   
 
3.2.2.5. ELISA 
The media for each of the five adipogenesis treatment groups were 
collected at Day 20 to assay for leptin and adiponectin secretion using the 
ELISA kits in accordance to manufacturer’s instruction.  The media were 
separately concentrated approximately 80 times using the Amicon
 
Ultra-15 10k 
centrifugal filter device.  Total protein concentration was quantified by Braford 
protein assay before sample loading to ensure equal amount of total protein was 
loaded into each ELISA well.   The intensity of colour change was measured at 
450 nm using Tecan Infinite 200 series microplate reader (Männedorf, 
Switzerland).  Data acquired were analysed using the one-way ANOVA with 




All images are representatives of the assays, which were carried out in 
triplicates for each umbilical cord lining sample.  
 
3.3.1. Umbilical cord lining mesenchymal cells 
UCLMCs were readily available from the umbilical cord lining.  The 
cells showed high proliferation activity and were easily maintained in the 
proprietary medium.  They had spindle-like, fibroblastic morphology as 




Fig. 3-2. Naive umbilical cord lining mesenchymal cells. 










3.3.2. Morphology and Oil Red O staining 
The morphology of UCLMCs that were subjected to differentiation was 
observed to change from spindle-like fibroblastic cells at Day 0 (Fig. 3-2) to 
irregular, cuboidal-shaped cells that were adipocyte-like at Day 20 (Fig. 3-3).  
The intensity of Oil Red O stain in all four treatment groups gradually increased 
from Day 1 to Day 20, indicating accumulation of lipid droplets.  Within the low 
glucose treatment groups, higher insulin concentration resulted in more cells 
with lipid accumulation.  The same phenomenon was observed for the high 
glucose treatment groups. The sizes and accumulation rates of lipid droplets 
between LGHI and HGLI groups were not significantly different.   
 
Among the four treatment groups, it was observed that rate of 
accumulation of lipid droplets in cells was the slowest in LGLI group and fastest 
in HGHI group.  In addition, the lipid droplets of cells cultured in LGLI 
adipogenic medium were generally smaller in size as compared to those in 
HGHI adipogenic medium.  At Day 20, the HGHI group showed the greatest 
intensity of Oil Red O stain.  Tiny intracytoplasmic lipid droplets were observed 
in the control group.  These tiny lipid droplets in naive UCLMCs were different 
from those observed in adipogenesis treatment groups, as the droplets were 
uniformly minute in size without any increment in amount nor size over the 20 
days.  On the other hand, more lipid droplets appeared over the 20 days in 
differentiation-induced groups and they coalesced to form bigger lipid droplets 
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Fig. 3-3. Oil Red O Stain of lipid droplets in differentiating UCLMCs. 
N: control, LGLI: low-glucose low-insulin, LGHI: low-glucose high-insulin, HGLI: high-
glucose low-insulin, HGHI: high-glucose high-insulin.  At Day 20, highest intensity of 
Oil Red O stain for lipids was seen in HGHI group as indicated by yellow 





There was a gradual upregulation in the gene expression of adipsin for 
all differentiation-induced groups (Fig. 3-4).  Statistical analysis of band 
intensity signals at Day 20 by one-way ANOVA showed there was significant 
difference between control and induced groups, but there was no significant 
difference in the gene expression intensity among all differentiation-induced 
groups (Fig. 3-5).  For details of relative band intensity of adipsin, please refer 
to appendix 1-1. 
 
PPAR 
There was an obvious upregulation in the gene expression of PPAR for 
all differentiation-induced groups (Fig. 3-4).  No gene expression was observed 
in the control group.  Statistical analysis of band intensity signals at Day 20 by 
one-way ANOVA showed significant difference between control and induced 
groups, but no significant difference among all differentiation-induced groups 
(Fig. 3-5).   The primer sequence used in this study recognized cDNA common 
to 1 and 2 isoforms.  For details of relative band intensity of PPARγ, please 














Fig. 3-4. Gel electrophoresis of RT-PCR product. 
Gene expression for PPAR was observed in all adipogenic-induced groups starting from Day 3 and all through Day 20 of the experiment, while 
it was absence in control group.  This is indicated that adipogenesis was initiated and ongoing.  In addition, the gradual upregulation of adipsin 
expression in all adipogenic-induced groups indicated gradual maturation of the ALCs as adipsin is known to be a secreted factor of matured 
adipocytes.  (GAPD:  glyceraldehyde-3-phosphate dehydrogenase)
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Fig. 3-5. Relative band intensity of RT-PCR bands for adipsin and PPAR. 
After 20 days of differentiation, one-way ANOVA showed that there is 
significant increase in the level of adipsin and PPAR expression in all 
differentiation-induced groups as compared to control group.  Tukey’s pairwise 
comparison showed no significant difference in the level of gene expression 











Limit of detection for leptin by the assay kit is 6 pg/ml.  Amount of 
secretion by naive UCLMCs at Day 20 was below the recommended limits of 
detection (Fig. 3-6).  Data analysis by one-way ANOVA showed that there was 
no significant difference in the leptin secretion between cells incubated in high 
glucose medium and those of control group.  However, the amount of leptin 
secreted by matured ALCs incubated in low glucose medium groups was 
significantly more than those in control group (p < 0.001).  A further data 
analysis by two-way ANOVA on the effect of glucose and insulin 
concentrations and potential interactions between glucose and insulin revealed 
that their concentrations significantly influenced the secretion of leptin (p < 
0.001 and p < 0.05, respectively).  There was no significant interaction between 
the two factors (p > 0.05). 
 
Adiponectin 
Limit of detection for adiponectin by the assay kit is 10 pg/ml.  Although 
there was faint detection of adiponectin secretion by naive UCLMCs and ALCs 
incubated in high glucose medium at Day 20, the amounts measured were below 
the recommended limit of detection (Fig. 3-6).  Data analysis by one-way 
ANOVA showed that different concentrations of glucose and insulin have 
significant effect on the amount of adiponectin secreted.  Tukey’s test identified 
significant differences between the cells in control group and those in low 
glucose groups (p < 0.001).  A further data analysis by two-way ANOVA 
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showed that the concentration of glucose has significant effect (p < 0.001), 
while the concentration of insulin has no significant effect on the amount of 
adiponectin secretion (p > 0.05).  There was no significant interaction between 
the two factors (p > 0.05). 
 
Fig. 3-6. Adipocytokines secretion by ALCs at Day 20. 
Limits of detection for adiponectin and leptin by the ELISA kit is 10 pg/ml and 
6 pg/ml respectively, hence readings below the limits are detectable but unable 
to be quantified accurately.  Adiponectin: one-way ANOVA, Tukey’s test 
showed significant difference between low glucose adipogenic and naive 
UCLMCs group (p < 0.001).  Two-way ANOVA did not show any interaction 
between glucose and insulin (p > 0.05).  Leptin: one-way ANOVA, Tukey’s test 
showed significant difference between low glucose adipogenic and naive 
UCLMCs group (p < 0.001).  Two-way ANOVA showed that both insulin (p < 
0.05) and glucose (p < 0.001) concentrations affect the amount of leptin secreted, 
but the two factors did not have any interactions (p > 0.05).  Amounts of 
adiponectin in naive UCLMCs, HGLI and HGHI groups were below 10 pg/ml.  
Amounts of leptin in naive UCLMCs and HGLI groups were below 6 pg/ml. 
Values are mean  SEM.  *Indicates significant difference by one-way ANOVA.               
*t indicates significant difference by t-test.  
 
Naive 
UCLMCs LGLI LGHI HGLI HGHI 
Adiponectin 0.87 ± 1.21 313.56 ± 105.55 292.81 ± 91.62 1.63 ± 2.24 1.06 ± 2.40 









In this study, we observed that mesenchymal progenitor cells from the 
human umbilical cord lining by tissue explant method can be easily maintained 
and expanded in vitro.  Although very tiny intraplasmic lipid droplets were seen 
in naive UCLMCs via Oil Red O staining, the general morphology of the naive 
UCLMCs remained spindle-like and fibroblastic.  Additionally, the extra-
cellular matrix remained as a closely-packed regular network.  This is a stark 
contrast to the irregular and cuboidal shape of adipocytes, and loose stromal of 
adipose tissues.  Drastic changes in appearance of the cells are rudimentary 
indication of differentiation.  Therefore it is inferred that the UCLMCs did not 
undergo adipogenesis in the absence of adipogenic inducers.  The involvement 
of insulin/IGF-1, glucocorticoid and cAMP signalling pathways in adipogenesis, 
as well as the varying requirement of induction due to different responsiveness 
of specific cell culture models has been well reviewed [93, 101, 107].  For 
serum-containing media of these reports, the standard adipogenic cocktail 
contains insulin, dexamethasone and IBMX which is in agreement with the 
adipogenic cocktail used in our study.  Hence notwithstanding the different 
insulin and glucose concentrations, we observed that UCLMCs were stimulated 
to differentiate into ALCs at Day 20.   
 
All differentiation-treated groups had circular cellular morphology of 
various sizes and significant accumulation of lipid droplets within the cytoplasm, 
which is similar to typical adipocytes.  From this 2
2
 factorial design study, it can 
be deduced that the rate and extend of adipogenesis were influenced by the 
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concentrations of insulin and glucose.  It was observed that higher 
concentrations of glucose and insulin resulted in faster and more accumulation 
of lipid, indicated by the most intense Oil Red O stain seen in the HGHI group. 
 
Adipogenesis in UCLMCs was also confirmed at the genetic level, 
where there was upregulation of the adipsin and PPAR gene expression in all 
differentiation-treatment groups.  Adipsin is an immune system-related serine 
protease found to be identical to complement factor D [108].  It is synthesized 
predominantly in adipose tissues and secreted into the blood stream. It was 
noted to be down-regulated in several, but not all, models of obesity.  Johnson’s 
group [109] reported a reduced adipsin mRNA and protein in genetically obese 
Zucker rats.  Lowell and his colleagues [110] reported a decreased adipsin 
expression early in the development of obesity in the ob/ob obese mouse model.  
However in human studies, adipsin was found to be higher with increased body 
mass [96, 97].  The up-regulation of adipsin gene expression during 
adipogenesis in the present study correlates well with similar observation 
reported by other research groups [106, 111].  PPAR is the most adipose 
specific of the PPARs subfamily of nuclear hormone receptors, and exists as 
two isoforms of PPAR1 and PPAR2.   It was demonstrated that PPAR 
regulates development of adipocyte lineage because its ectopic expression is 
able to trigger adipogenesis in fibroblast and muscle cells [112].  The increased 
expression of PPAR gene observed in this study is evident that UCLMCs had 
undergone adipogenesis.  This is consistent with observations by other groups 
dealing with mesenchymal cells [99, 106, 113].  It is expected that there is no 
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PPAR gene expression in naive UCLMCs, as this gene is induced only before 
transcriptional activation of most adipocyte genes [93].  There is no significant 
difference in the intensity of gene expression among the four differentiation-
treatment groups.  This suggests that together with other adipogenic-inducing 
agents, glucose concentration of 1 mg/ml and insulin concentration of 10 µg/ml 
were sufficient to initiate adipogenesis of UCLMCs.  Increasing the 
concentrations of both factors did not affect the extent of initiating 
differentiation.   
 
Mature adipocytes are known to secrete leptin and adiponectin [93].  
Leptin, a 16 kD ob gene product, is one of the most important adipose-derived 
hormones.  It plays a key role in regulating energy intake and expenditure, 
including appetite and metabolism [114].  The feedback regulatory loop acts via 
hypothalamic receptors to inhibit feeding and increase thermogenesis, resulting 
in a decrease in body weight. Serum leptin level correlates with fat mass, 
increases with obesity and is significantly higher in women than men even after 
adjustment for fat mass [115, 116].  Adiponectin, a 30 kDa protein, has been 
shown to have a role in the regulation of glucose and lipid homeostasis and a 
paradoxical decrease in obesity and Type 2 diabetes [117-119].  It is the most 
abundant hormone secreted by adipose tissue, and has an inverse relationship 
with leptin.  Its plasma concentrations are 1000 or more folds higher than that of 
leptin, ranging from 1.9 to 17.0 mg/ml in healthy volunteers [119-121].  
Körner’s team demonstrated that adiponectin synthesis and secretion occurred 
specifically in mature adipocytes in human adipocyte cell culture, and therefore 
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adiponectin could serve as a distinctive marker of adipocyte differentiation 
[122].   
 
In our study, the differentiated UCLMCs after 20 days of incubation in 
low glucose adipogenic medium secreted more adiponectin (LGLI: 313.6  
105.6 pg/5 g total protein, LGHI: 292.8  91.2 pg/ 5g total protein) and leptin 
(LGLI: 39.1  18.9 pg/ 5g total protein, LGHI: 50.6  11.3 pg/ 5g total 
protein) compared to naive UCLMCs (adiponectin: 0.9  1.2 pg/5 g total 
protein, leptin: 1.2  2.0 pg/5 g total protein) at Day 20.  This indicates that the 
UCLMCs had differentiated into mature ALCs mimicking the physiological 
adipocytokine secretion paradigm in normal-weight adults, where more 
adiponectin is present than leptin in the plasma.  On the other hand, the amount 
of adipocytokines secreted by ALCs incubated in high glucose adipogenic 
medium decreased drastically by approximately 300-folds for adiponectin and 
5-folds for leptin.  The decrease in adiponectin secretion is liken to the same 
phenomenon in obesity.   
 
From other studies on obesity, the inverse relationship between 
adiponectin and leptin concentrations should produce a fall in adiponectin level 
and a rise in leptin level [119-121].  The lack of reduction in food intake and 
increase in energy expenditure despite elevated leptin concentration in human 
obesity has been linked to leptin resistance [123]. One of the mechanisms 
thought to account for leptin resistance is a defect in the transporter system of 
leptin through the blood-brain barrier, thus leptin is less efficient in obese 
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individuals [123-125].  The deficient in feedback regulatory mechanism leads to 
compensatory increase in leptin secretion to sustain regulation of energy intake 
and expenditure.  With due consideration that the huge difference in magnitude 
of the adipocytokine secretion between low and high glucose treatments may 
render the two-way ANOVA less sensitive in detecting statistical significance, 
supplementary individual t-test was carried out between each differentiation 
treatment group and naive UCLMCs.  The t-test result for ALCs in low glucose 
differentiation media showed significant differences for leptin and adiponectin 
secretion, which matched the result of two-way ANOVA.  On the other hand, 
for comparison between naive UCLMCs and ALCs in high glucose 
differentiation media, the t-test showed no significant difference for adiponectin 
secretion but significant difference for leptin secretion.  This t-test result is 
different from that of two-way ANOVA, which failed to detect the statistical 
difference for leptin secretion.  Therefore our in vitro study shows that ALCs 
incubated in high glucose medium is similar to adipocytes in obese individuals, 
where there is very low adiponectin secretion and high leptin secretion.   
 
Given the previous findings that leptin concentration increases with fat 
mass [115, 116] and the close resemblance of our ALCs in high glucose medium 
to adipocytes in obesity, leptin secretion was expected to be higher in high 
glucose treatment groups than low glucose treatment groups.  However this was 
not observed.  The development of in vivo obesity involves a complex interplay 
of numerous cellular signals and pathways that has yet to be fully elucidated.  
The influence of other biochemical signalling such as those from the 
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hypothalamus, on the overall increase in leptin concentration in obesity is 
beyond the scope of our study.   
 
The above results taken together demonstrate that in the presence of 
adipogenic media, depending on concentration of glucose used, the UCLMCs 
can be induced to ALCs resembling those of normal-weight or obese individuals.  
Under low glucose culture condition, the ALCs obtained are comparable to 
adipocytes of normal-weight individuals as it secretes more adiponectin than 
leptin.  Whereas under high glucose culture condition, the ALCs obtained is 
liken to adipocytes of obese individuals due to the extremely small amount of 
adiponectin secreted.  In addition, higher concentration of insulin enhanced 
lipogenesis. 
 
 Studies relating to MSCs have revolved around the characterisation of 
the cells and comparative studies of the stemness and differentiation abilities of 
the MSCs from various sources.  To the best of our knowledge, our study is 
novel and different from the reports on progenitor cells as we demonstrated the 
influence of changing glucose and insulin concentrations on in vitro 
adipogenesis by ALCs.  We have shown that UCLMCs can be developed for 
research on adipogenesis and pathology of obesity via manipulation of the 




CHAPTER 4: DIFFERENTIATION OF UCLECS TO 
HEPATOCYTE-LIKE CELLS 
4.1. Introduction 
4.1.1. Liver - the organ of life 
The liver is the largest glandular organ in the body.  It has endocrine-like 
functions which include modification of the structures and functions of 
thyroxine and growth hormones, and also exocrine function represented by its 
involvement in bile production.  It is also the body’s main detoxifying system 
synthesizing circulating plasma proteins and has an important role in glycogen 
storage and gluconeogenesis, as well as maintaining homeostasis of vitamins A, 
D, K and iron [126].  Hence the liver is a vital organ for regulating normal 
physiology.  Due to numerous intimate functions of the liver and other 
endocrine and digestive organs, the importance of liver for the sustenance of 
healthy life cannot be overemphasised.  All nutrients and medications, after 
absorption from the intestines, are first presented to the liver for 
biotransformation before distribution or elimination, hence making the organ 
most vulnerable to any xenobiotic insult.   
 
An ailing liver will inevitably lead to a broad spectrum of diseases, 
which ultimately becomes a hefty healthcare burden.  Currently, an estimated 
5.5 million Americans have chronic liver disease, and more than 20 million have 
gallbladder disease, incurring total economic cost per year of approximately 
USD1.6 billion for chronic liver disease and cirrhosis, USD1.3 billion for liver 
cancer, and USD6 billion for gallbladder disease.  With concerns for the 
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immense burden that liver and biliary diseases will impose on society, an Action 
Plan for Liver Disease Research was set up in the United States to identify areas 
of scientific opportunity in the prevention, diagnosis, and management of these 
debilitating diseases [127].  For individuals with acute liver failure, end-stage 
liver diseases or biliary atresia, the only effective treatment is liver 
transplantation.  Unfortunately, the availability of suitable liver for 
transplantation is scarce as the number of patients in need of the organ outstrips 
the number of donors.  Based on the Organ Procurement and Transplant 
Network (OPTN) data as of 12 January 2011, there are 16, 857 patients on the 
wait list for liver, while there were only 5,779 donors in year 2010.  Although 
recent advance technology has made bioartificial liver devices a possible 
alternative, the devices are still at the clinical development stage.  The major 
stumbling block to establish these devices commercially is the lack of reliable 
and sustainable cell source [128, 129].   
 
The liver has the ability to regenerate itself rapidly as seen in rodent 
experimental models [130, 131].  When 70% of the adult liver is surgically 
dissected, the original mass and function are recovered within a week.  Given 
the strong regenerative capabilities of the liver, it seems plausible to call for 
healthy volunteers to donate part of their livers to patients in desperate need of 
the organ and hence there should not be shortage of livers for transplant.  
However, looking at the statistics from OPTN, this optimistic scenario is 




The fruitless wait for organ donors had prompted scientists to search for 
alternative solutions.  Hopes have been pinned on stem cells, which are highly 
regarded for their roles in regenerative medicine and applications in 
developmental studies. 
 
4.1.2. Hepatogenesis and hepatocytes 
Early in the third week of human embryogenesis, the liver develops from 
the endoderm germ layer, specifically arising from the floor of the foregut to 
form the hepatic diverticulum (Fig. 4-1) [126].  Endoderm cells that line the 
diverticulum at this stage are called hepatoblasts, which upon receiving signals 
from a network of transcription factors, proliferate and differentiate into 
hepatocytes.  The hepatoblasts have the potential to differentiate into either 
cholangiocytes or hepatocytes.  Six transcription factors: HNF1α, HNF1β, 
HNF3β, HNF4α1, HNF6 and LRH-1, were found to form the core of the 
regulatory network that determines the hepatic fate [132].   
 
Fig. 4-1. Sagittal midline section of embryos at developmental stages. 
 (A) 17 days, (B) 22 days, white arrows: head fold, black arrows: tail fold.  The 
liver starts to develop early in the third week of embryogenesis from the distal 




It was found that HNF4α is essential for normal liver architecture and 
functional differentiation of hepatocytes, including the organization of the 
sinusoidal endothelium.  HNF4α exists in several isoforms.  It is an important 
regulator of hepatogenesis as it activates a cascade of transcription factors that 
define the gene expression profile of mature hepatocytes (Fig. 4-2) [134].  In 
HNF4α-deficient livers, the formation of gap junctions is disrupted.  The mutant 
hepatocytes did not make normal cell-cell contacts and had unusual spaces 
between the membranes of neighbouring cells [135, 136]. 
 
As mentioned in Chapter 1, many studies have reported the potential use 
of undifferentiated and differentiated ASCs for cellular therapy [8, 33, 137].  
Promising results of MSC-differentiated hepatocyte-like cells (HLCs) as an 
option for in vitro drug metabolism studies and liver cell therapy have been 
reported [138-140].  We thus aim to differentiate UCLECs obtained from the 
same explant-isolation method into HLCs by assessing phenotypic and 






Fig. 4-2. Schematic of CYP gene expression mechanisms.   
CBP: CREB-binding protein, C/EBP: CCAAT-enhancer-binding protein, COUP-TFs: chicken 
ovalbumin upstream promoter transcription factors, LAP: liver-enriched transcriptional 
activating protein, LIP: liver-enriched transcriptional inhibitory protein, NCoR: nuclear receptor 
corepressor, NR: nuclear receptors, SHP: small heterodimeric partner, SMRT: silencing 
mediator of retinoid and thyroid receptor, Sp1: Specificity Protein 1, SRC: steroid receptor 
coactivator, TcAs: transcriptional coactivators, TcRs: transcriptional corepressors.  
Expressions of CYP genes depend on an orchestrated network of key liver-
enriched transcription factors (LETFs): C/EBP and HNFs -1, -3 and -4.  In 
addition, interactions with TcAs are essential for activation of LETFs for its 
proper functionality.  Two protein isoforms are produced from C/EBPβ mRNA: 
LAP and LIP.  Sp1 interacts with C/EBPβ to enhance genes transcription.  There 
are five possible mechanisms that lead to impaired expression of CYP genes. (1) 
Increase in TcRs which interact with NR to recruit core histone deacetylase 
complexes, and hence results in transcription silencing.  (2) Suppressive effect 
of COUP-TFs on key transcription factors. (3) Inhibition of HNF4 
transactivation by the SHP.  (4) Methylation of DNA and histone decetylation 
lead to more compact chromatin structures which render binding sites 
inaccessible by LETFs and TcAs.  (5) Increase expression of LIP, a dominant 
negative-regulator of transcription, brings about CYP gene suppression due to 





4.2. Materials and Methods 
4.2.1. Materials 
All chemical reagents were purchased from Sigma Aldrich (St Louis, 
MO, USA) unless otherwise stated.  Antibiotic-antimycotic solution, Dulbecco’s 
Modified Eagle Medium without phenol red and Dulbecco’s Modified Eagle 
Medium (DMEM) were from Gibco (Carldbad, CA, USA).  Fetal bovine serum 
(FBS) was from Hyclone, Thermo Scientific (Waltham, MA, USA).  Medium 
171 was from Cascade Biologics (Portland, OR, USA).  Hepatocyte culture 
medium with supplements and growth factors (HCM™ Bulletkit®) and 
hepatocyte maintenance medium (HMM™) were purchased from Lonza 
(Walkersville, MD, USA).  HepG2 cancer cell line from ATCC was cultured in 
accordance to supplier’s recommendation in DMEM containing 10% FBS.  
NHeps non-malignant cryopreserved human hepatocytes were from Lonza 
(Walkersville, MD, USA).  Primary antibodies alpha fetal protein (AFP) was 
from Neomarkers (Fremont, CA, USA), cytokeratin 18 (KRT18) and 19 
(KRT19) were from Abcam® (Cambridge, UK).  Albumin primary antibody 
and Liquid DAB+ substrate chromogen system was from Dako (Carpinteria, CA, 
USA), R.T.U Vectastain® Universal Quick kit which contains 2.5% normal 
horse serum, pan-specific biotinylated antibody and streptavidin peroxidase 
preformed complex, was from Vector Laboratories, Inc. (Burlingame, CA, 
USA).  Secondary antibodies chicken-antirabbit and chicken-antimouse Alexa 
Fluor 488 were from Invitrogen™. Periodic acid-Schiff kit and 4',6-diamidino-
2-phenylindole (DAPI) were from Sigma Aldrich.  Formaldehyde was from ICN 
Biomedical, Inc (Aurora, OH, USA).  The RNA extraction RNeasy
®
 Mini kit 
and RNase-Free DNase set were purchased from Qiagen
®
 (Hilden, Germany).  
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β-mercaptoethanol was from ICN Biomedical, Inc.  Oligonucleotide and 10x 
TAE buffer were from 1st Base, Singapore.  All primers, ReactionReady™ 
Human GAPD internal normaliser, and ReactionReady™ Hotstart “Sweet” PCR 
Master mix were purchased from SABiosciences™ (Frederick, MD, USA).  The 
SuperScript™ III Reverse Transcriptase and Ultrapure agarose powder were 
from Invitrogen™.  Gel Red™ was from Biotium, Inc (Hayward, CA, USA).  
Loading dye and 100bp DNA ladder were from Promega (Madison, WI, USA).  
All drug compounds were from Sigma-Aldrich.   
 
4.2.2. Methods 
4.2.2.1. Source of UCLECs 
Collection and processing of the umbilical cords were as mentioned in 
Chapter 3, methods, section 3.2.2.1.  For expansion of UCLECs, the proprietary 
medium, PTTe1 was made up of Medium 171 supplemented with 2.5% FBS, 50 
µg/ml IGF-1, 50 µg/ml PDGF-BB, 5 µg/ml TGF-β1 and 5 µg/ml insulin.  
UCLECs from three different umbilical cords were randomly selected from the 
specimen bank of CellResearch Corporation, Singapore.  Each set of experiment 
was carried out in triplicates.  The UCLECs used in the experiment were at 
either passage 3 or 4.   
 
4.2.2.2. Hepatogenesis 
The UCLECs were plated at a density of 5000 cells/cm
2
 and cultured at 
37
o
C in an atmosphere of 95% air and 5% carbon dioxide.  Upon reaching 
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confluency at passage 3 or 4, the PTTe1 medium was removed and replaced 
with HCM™.  Differentiation was carried out over a period of 28 days, where 
the UCLECs were cultured in HCM™ for 14 days, followed by HMM™ for 
another 14 days.  The media were refreshed every 2 to 3 days.  (For content of 
HCM™ and HMM™, please refer to appendix 2.) 
 
Hepatocellular carcinoma, HepG2 cell line and cryopreserved normal 
human hepatocytes (NHeps) were used as controls.  HepG2 cell line from 
ATCC was cultured in accordance to supplier’s recommendation in DMEM 
containing 10% FBS.  NHeps from Lonza (Walkersville, MD, USA) were 
seeded onto 24-well plates pre-coated with 60 µg/cm
2
 Type 1 collagen in 
accordance to supplier’s recommendations and maintained in HCM™ for 48 to 
72 hrs to allow for cell recovery and attachment before assays were carried out.  
Media were refreshed everyday.  
 
4.2.2.3. Immunocytochemical and immunofluorescence staining 
For purpose of staining, autoclaved 12-mm coverslips were inserted into 
each well of 24-well plates before seeding and differentiation of UCLECs.   On 
Days 0, 7, 14, 21 and 28, the required number of coverslips for histological 
staining was carefully fished out from each well using sterile forceps.  Each 
coverslip was gently dipped into sterile PBS twice to rinse off any residual 
media.  This procedure was carried out in the biohazard hood before the 
coverslips were transferred out onto the bench top for subsequent fixation and 
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staining as stated below.  For ease of handling, the coverslips were glued down 
onto glass slides after respective fixation before the initiation of staining steps. 
 
Immunocytochemical: AFP 
Briefly, the cells were fixed in 4% v/v paraformaldehyde for 30 min, 
then blocked with 2.5% normal horse serum for 20 min, followed by incubation 
with primary antibody for 90 min, and pan-specific secondary antibody for 30 
min.  Following incubation with streptavidin horseradish peroxidase, DAB+ 
substrate chromogen system was used in accordance to manufacturer’s 
recommendation.  Cell staining was visualised under light microscopy. 
 
Immunofluorescence: albumin, KRT18, KRT19 
Cells were fixed with methanol at -20
o
C for 10 min then blocked with 
2.5% normal horse serum for 20 min, followed by incubation with primary 
antibody for 90 min, Alexa Fluor 488 secondary antibody for 30 min and DAPI 
for 10 min.  Cell staining was visualised under Carl Zeiss Apotome microscope 
(Jena, Germany). 
 
4.2.2.4. Periodic acid-Schiff Staining 
Briefly, the cells were fixed in 4% v/v paraformaldehyde for 30 min at 
room temperature then permeabilised with 0.1% v/v Triton-X for 10 min.  Cells 
were oxidised in Periodic acid solution for 5 min, then washed several times 
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with milliQ water.  This is followed by treatment with Schiff’s reagent for 15 
min then washed under running tap water for 5 min.  Their nuclei were 
counterstained with hematoxylin for 1 min then blued with 1% v/v ammonia 
solution.   
 
4.2.2.5. Reverse transcription-PCR (RT-PCR) 
Total RNA was extracted using the kit in accordance to Qiagen
®’s 
instruction, and the optional on-column DNase digestion was performed with 
the RNase-Free DNase set to eliminate genomic DNA contamination.  cDNA 
synthesis was carried out in according to the steps stated in Fig. 4-3, followed by 
amplification of the first-strand cDNA at the required temperature (Fig. 4-4).  
Each 25 µl reaction contains 2 µl of cDNA.  The PCR end-products were 
electrophoresed on 2% w/v agarose gel containing Gel Red™ in 1x TAE buffer 
and visualised under UV light.  RT-PCR was performed in triplicates for each 






Fig. 4-3.  cDNA synthesis.   





Fig. 4-4. RT-PCR thermal cycling.   









All images are representatives of the assays, which were carried out in 
triplicates for each umbilical cord lining sample. 
 
4.3.1. General morphology 
Over the period of 28 days of differentiation, the morphology of the 
UCLECs changed from elongated, fibroblastic cells (Fig. 4-5) to rotund, 
polygonal hepatocyte-like cells and the nucleus occupied a large part of each 
cell.  In addition, it was observed that arrangement of the cells changed from 




Fig. 4-5. Naive UCLECs at confluency.  
Picture taken under light microscopy.  Undifferentiated UCLECs are spindle-








Fig. 4-6. Morphological changes of UCLECs over 28 days of differentiation.   
Pictures were taken under light microscopy.  By Day 7, some rotund and 
polygonal cells were observed.  At Day 28, all the cells were randomly arranged 
and polyhedron shaped. 
 
 
4.3.2. Immunocytochemical stain: AFP 
After 28 days of hepatic induction, AFP expression was not detected in 
HLCs.  On the other hand, strong expression of AFP was observed in clusters of 
naive UCLECs (Fig. 4-7).  In HepG2, which acts as a positive control for AFP 




Fig. 4-7. Immunocytochemical stain for AFP in HLCs.   
Pictures in left column were taken at 20X magnification, pictures in right 
column were taken at 40X magnification.  The absence of AFP expression and 
hepatocyte-like morphology of Day 28 HLCs indicated that the differentiated 
cells are non-malignant adult HLCs.  Distinct clusters of AFP expression were 





Fig. 4-8. Immunocytochemical stain for AFP in HepG2.  
(A) Positive expression of AFP, (B) No antibody control.  Distinct staining of 
AFP expression in HepG2 is an indication of the malignant nature of the cells.  
The absence of brown stain in (B) demonstrations the specificity of the AFP 
antibody used in the experiment.   
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4.3.3. Immunofluorescence stain: Albumin, KRT18, KRT19 
Naive UCLECs neither express albumin nor KRT18.  Albumin 
expression increased steadily over the 28 days as differentiation progressed (Fig. 
4-9).  By Day 21, there was clear accumulation of albumin in cytoplasm of the 
cells.  At Day 28, the spheroidal shape of each cell is highlighted by the albumin 
staining within the cytoplasm.  KRT18 expression was observed during first 2 
weeks of differentiation (Fig. 4-10).  At Day 21, its expression seemed to be 
transiently down-regulated before re-expressing again at Day 28.    KRT19 
expression was detected in naive UCLECs (Fig. 4-11).  There was a gradual 
down regulation of KRT19 starting from Day 14 of differentiation.  By Day 28, 
the KRT19 expression was faint or hardly visible.  Based on DAPI stain of the 
nucleus, it can be seen that the morphology consistently changed from oval 





Fig. 4-9. Immunofluorescence stain for albumin expressions.  
Naive UCLECs did not express albumin.  As hepatic differentiation progressed 
over 28 days, there was gradual increase in albumin expression as UCLECs 
became more hepatic-like. 
 
 
Fig. 4-10. Immunofluorescence stain for KRT18 expressions.  
Dynamic expression of KRT18 correlated well with cytoskeletal changes and 






Fig. 4-11. Immunofluorescence stain for KRT19 expressions.   
As hepatic differentiation progressed, the expression of KRT19 diminished over 
time.  This observation is consistent with human liver development where 
precursor cells moved away from biliary lineage towards hepatocyte lineage.   
Expression of KRT19 in adult hepatocytes is an indication of malignancy, as 




4.3.4. Periodic acid-Schiff stain 
Periodic acid-Schiff stain (PAS) was almost absent at Day 7 
differentiation.  Starting from Day 14 of differentiation, the fuchsia pink stain 
can be seen, indicating glycogen storage ability of the HLCs (Fig. 4-12).  
Maintenance of HLCs in HMM for an additional 7 days till day 35 did not show 
any greater accumulation of glycogen as compared to Day 28. 
 
Fig. 4-12. Periodic Acid Stain for glycogen storage abilities.  
(A) PAS staining at 7-day intervals during the 35 days of hepatic induction.   
Prominent fuchsia pink stain starting from Day 14 indicates accumulation of 
glycogen within differentiated UCLECs.  (B) Negative PAS staining of naive 
UCLECs (Day 0). 
 
 
4.3.5. RT-PCR  
Gene expression of the hepatic marker, HNF4α and the four cytochrome 
P450 enzymes in question were observed in NHeps as expected (Fig. 4-13).  
The HLCs was observed to express HNF4α, however it is a splice variant of the 
primer used in this study as indicated by the different band sizes from NHeps 
and HepG2.  Expressions of CYP1A2, CYP2D6, and CYP3A4 were observed in 
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HLCs, but no CYP2C9 was detected.  HepG2 expressed HNF4α strongly, while 
CYP1A2 and CYP2D6 gene expression were relatively weaker compared to that 




Fig. 4-13. Gel electrophoresis of RT-PCR product.   
(M) 100bp DNA ladder, (Lane 1) HepG2, (Lane 2) Day 28 HLCs, (Lane 3) 
NHeps.  10 µl of RT-PCR end-product was loaded into each well.  Multiple 





It has been previously shown that UCLECs were easier to isolate and 
maintain [71, 80], compared to primary hepatocytes.  Using the tissue explant 
method and identical PTTe-1 proprietary medium mentioned in our study, Reza 
and team characterised the UCLECs and found them to express Mucin1, p63 
and most, but not all embryonic stem cell markers [71].  p63 is a critical initiator 
of epithelial stratification, as well as key regulator of cell adhesion and survival 
in progenitor cells in squamous epithelium.  This alluded to the highly 
proliferative and significant clonogenic abilities of UCLECs.  In addition, 
UCLECs are reported to have immunoregulatory effect [83], thus minimising 
the need for immunosuppressive drugs and risk of graft-versus-host disease.  In 
contrast, ESCs tend to form teratoma and also elicit immune responses when 
transplanted.  UCLECs are therefore more amenable to tissue regeneration and 
cellular therapy compared to ESCs. 
 
We illustrated in this study that UCLECs differentiated into hepatocyte-
like cells with hepatic morphology and gene expressions.  During the first 2 
weeks of differentiation, the HCM™ medium used for inducing hepatogenesis 
contained epidermal growth factor, transferrin, hydrocortisone and insulin, 
which are essential growth factors for hepatic differentiation.  Medium was 
changed to HMM™, containing only dexamethasone and insulin as supplement 
to allow further maturation and maintenance of the HLCs.   Over the 28-day 
hepatic differentiation, the UCLECs gradually changed from elongated, 
fibroblastic morphology to rotund, polyhedral shape.  In addition, the positive 
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PAS staining is evident that the differentiated UCLECs possessed glycogen 
storage abilities, like the mature hepatocytes.  AFP is expressed only in foetal 
liver cells and tapers off by adulthood.  Expression of AFP in the adult liver is 
an indication of hepatocarcinoma.  For that reason, AFP expression functions as 
a hepatic marker to distinguish the liver development stage [145].  Our 
observation of strong AFP immunohistochemical staining in naive UCLECs is 
thus not unexpected, as the UCLECs used is of foetal origin and in this study the 
cells were at an early passage of 3 to 4.  As the UCLECs went through mitotic 
expansion and migrated outwards away from the initial cell clusters, the AFP 
expression could gradually be lost in subsequent daughter clones as indicated by 
the weaken AFP stain in UCLECs further away from the initial cell clusters.  
Since AFP expression is expected to taper off in adults, this loss of expression in 
our study could be a reflection of natural cellular development in primary cells.  
The complete disappearance of AFP expression on day-28 HLCs is heartening 
because it demonstrates that these HLCs had acquired the adult hepatocyte 
phenotype and were less likely to be malignant.      
  
It is known that serum albumin is produced in the liver and hence the 
gradual increase in immunofluorescence stain for albumin is another indication 
of mature hepatic characteristics.  A dated study by Mizuno and Singer reported 
concentration and subsequent transfer of serum albumin from endoplasmic 
reticulum to the golgi apparatus of HepG2 cells, leading to a much higher 
concentration of the secretory protein in the golgi apparatus at cell steady state 
[146].  This is in line with our observation that the positive stained cell 
cytoplasm with small particles clustering at the circumferences of the HLCs at 
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Days 21 and 28, is probably due to transportation and accumulation of albumin 
to the golgi apparatus of the cells.   
 
Keratins are intermediate filament-forming proteins that provide 
mechanical support and other cellular functions in epithelial cells.  They are 
grouped into type I and type II subfamilies, and expressed as specific pairs in a 
cell lineage and differentiation manner, with KRT8/KRT18 being a most 
common pair found in hepatocytes and hepatoma cells [147].  The 
KRT8/KRT18 pair had been found to modulate cell adhesion and migration in 
hepatocytes and hepatoma cells [148].  There is  predisposition to liver injury 
and apoptosis in mice in the absence or mutation of KRT8 or KRT18 [149].   
The dynamic expression of KRT18 in HLCs correlates well with cytoskeletal 
changes and ECM rearrangement occurrence during cell differentiation and 
migration.  The re-expression of KRT18 at Day 28 is coveted as its presence is 
expected in normal hepatocytes for structural integrity.  The strong KRT18 
expression seen in HepG2 is nothing short of norm as tumour cells do 
proliferate and migrate rapidly.  Supporting our data is similar expression of 
hepatocyte-specific markers, albumin and KRT18 in HLCs differentiated from 
human placenta-derived multipotent cells, which is a cell source closely related 
to ours [150].   
 
Our observation of diminishing KRT19 expression is consistent with 
results of a study by Haruna and colleagues on human liver development [151].  
Analysis of keratin expression in adult, infant and foetal livers of 4 to 40 weeks 
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gestational age showed that KRT19 was one of the first markers detected in 
immature progenitor cells of the liver at 4 weeks’ gestation.  The progenitor 
cells continued to express KRT19 from 8 to 14 weeks’ gestation, and abrogated 
from the hepatoblasts at 14 to 16 weeks’ gestation.  In contrast, when progenitor 
cells transformed into ductal plate cells, KRT19 expression increased and 
persisted in differentiated bile ducts.  The gradual appearance of hepatic marker 
KRT18 and disappearance of biliary marker KRT19 render that the multipotent 
UCLECs is moving towards commitment into unipotent hepatocyte lineage.  
These respective up and down regulation of hepatocyte and cholangiocyte 
markers resembled in vivo hepatogenesis [145] as the bipotent hepatoblasts 
moved away from biliary lineage towards hepatocyte lineage.   
  
The presence of metabolic enzymes is an ultimate determination of 
terminal stage of liver organogenesis.  In our analysis of Day 28 HLCs at the 
genetic level by RT-PCR, varying amount of cytochrome P450 transcripts was 
expressed.  Although gene expressions of CYP1A2, CYP2D6 and CYP3A4 are 
much lower than that of NHeps, the sheer gene expressions of these cytochrome 
enzymes indicated the HLCs are considerably at the terminal stage of hepatic 
differentiation.  In a review by Donato and workers, comparative expression of 
P450 transcripts in HepG2 against primary human hepatocytes was reported to 
be a mere 0.01% for CYP2C9, 0.03% for CYP1A2 and CYP3A4, and 1.57% for 
CYP2D6 [152].  Despite the low gene expression of metabolic enzymes, HepG2 
is still widely used in hepatic studies [153-156] due to the shortage of human 
hepatocytes and the lack of better alternative cell-based system.   
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Furthermore, HNF4α gene was found to be expressed by HLCs.  It is 
mentioned in the manufacturer’s product information leaflet of the HNF4α 
primers that their primers can also generate amplicons from splice variants or 
alternative transcripts.  Hence the observed difference in HNF4α band size of 
HLCs from HepG2 and NHeps is likely due to splicing variant of the gene in 
HLCs.  All HNF4α isoforms are capable of binding to the regulatory regions of 
the cytochrome P450 genes with different activating properties [141].  As 
mentioned earlier in this chapter, there are several possible mechanisms that 
lead to impairment of cytochrome gene expression in hepatic cell lines.   It was 
shown that blockage of HNF4 translation down-regulated CYP3A4, CYP3A5 
and CYP2A6 expressions, moderately inhibited CYP2B6, CYP2C9 and 
CYP2D6 expressions, whereas CYP2E1 expression was unaffected [157].  
Therefore the suppressed CYP2C9 gene expression in HLCs could be a 
consequence of low expression of the HNF4α variant similar to NHeps, an 
isoform necessary for activating CYP2C9.   
 
Our study illustrated that UCLECs-derived HLCs can be developed and 
they have morphology that closely resemble mature hepatocytes.  Furthermore 
naive UCLECs were shown to express AFP and KRT19, markers which have 
been found in hepatoblasts [158].  Although it has been shown that bone marrow 
derived PSCs were able to differentiate to HLCs, these hepatoblasts markers 
were not expressed by PSCs [139, 159].  This indicates that naive UCLECs may 
have the propensity to differentiate into HLCs as compared to bone marrow 
derived PSCs.  Consequentially, the study of hepatogenesis in UCLECs will be 
less complicated and may have a closer resemblance to in vivo event.    
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Accordingly, with further characterization, the HLCs have potential applications 
in liver research.    
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Approximately 70% to 80% of the liver cell populations are hepatocytes, 
arranged in cellular cords, forming the parenchyma of the liver.  The 
hepatocytes work in close pace with the other liver cells such as the 
cholangiocytes, endothelial cells, sinusoidal endothelial cells, Kupffer cells, pit 
cells and hepatic stellate cells [126, 132, 160].  The metabolic function in adult 
liver is lacking in the foetal liver, which supports hematopoiesis instead.  The 
metabolic function of the liver is not critical in the foetus because the 
biotransformation task is done by the maternal liver and all nutrients are then 
supplied to the foetus through the umbilical cord.  As the foetus develops, the 
hematopoiesis function of the liver is gradually shifted to the bone marrow 
while the hepatocytes differentiate further to acquire metabolic functions so as 
to facilitate survival of the neonates base on their own metabolic functions upon 
birth [161]. 
 
Due to the diverse genetic make-up of different ethnic groups and 
individuals, the extensive polymorphisms of enzymes involved in metabolism 
made drug biotransformation studies a gruelling task.  However laborious, drug 
pharmacology and toxicology investigations are indispensible during drug 
discovery and development to screen for potential hazardous xenobiotics as 
drug-induced liver injury is the most common cause of acute liver failure.  The 
most ideal benchmark for in vitro metabolism studies is inarguably primary 
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hepatocytes.  Unfortunately, maintaining primary hepatocytes with its 
compendium of metabolism enzymes functional over the duration of 
metabolism studies is difficult [141, 162].  Furthermore, the batch-to-batch 
variation of enzyme levels in each individual due to changes in lifestyle, health 
status and environmental factors is the norm.  This and limited supply of 
primary hepatocytes pose additional challenges to the conduct of drug 
biotransformation studies and other research.  The search for alternative cell 
sources and in vitro drug study models is ongoing.  Subcellular fractions from 
hepatocytes, liver slices, cryopreserved hepatocytes and immortalised cell lines 
have been well reviewed for their use in drug distribution, metabolism and 
elimination studies [141, 162-164].   
 
5.1.1. Subcellular fractions 
Subcellular preparations that have been frequently used in in vitro drug 
biotransformation studies include supersomes, human liver microsomes (HLM), 
cytosol fractions and S9 fractions.  Supersomes are transfected insect cells that 
overexpressed human CYPs and uridine diphosphoglucuronosyl transferase 
(UGTs) to allow investigation of involvement by individual metabolic enzyme 
in drug biotransformation and drug-drug interactions.  Typically, supersomes 
system overexpresses a single biotransformation enzyme, hence the metabolism 
profile does not provide a complete picture  [165].  HLM are easily prepared 
from fresh or cryopreserved human liver tissues by homogenisation and 
differential centrifugation [166].  It is advantageous to use microsomes because 
it is well characterised, commercially available and low in cost.  In addition, the 
variability of HLM activities between individuals is easily overcome by pooling 
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microsomes from different individuals.  However, the microsomal preparations 
contain only UGTs and cytochrome P450 enzymes.  The absence of other 
enzymes and cytosolic cofactors connote an incomplete representation of the in 
vivo situation and hence will not be suitable for the quantitative measure of 
metabolites formed [165].  Liver cytosolic fraction obtained from differential 
centrifugation of liver homogenate contains only soluble phase II enzymes, and 
are therefore only useful for specific studies of biotransformation by phase II 
enzymes.  A better representation of in vivo metabolism is offered by liver S9 
fraction, which contains both microsomal and cytosolic fractions.  On the other 
hand, the overall lower enzyme activity in S9 fraction compared to microsomes 
or cytosol may result in some metabolites being overlooked [165].  On the 
whole, the different types of subcellular fractions are useful for specific studies.  
For a more complete representation of the in vivo milieu they have to be used in 
combination. 
 
5.1.2. Liver slices 
With the availability of high-precision tissue slicers, liver slices become 
the most ideal in vitro representation of drug biotransformation as there is 
normal spatial arrangement of the hepatocytes with the rest of the liver cells, and 
there are intact cellular interactions.  However, besides the shortage of liver 
tissue, it is difficult to work with liver slices as viability and CYP activity is 
short due to the poor penetration of culture medium and oxygen into the tissue 




5.1.3. Primary adult hepatocytes 
Drug biotransformation studies conducted in primary hepatocytes bear 
strong resemblances to in vivo conditions.  Compared to liver slices, 
investigation of cellular interactions with other non-hepatocyte cells is not 
possible due to the lack of these structures. The main advantages over liver 
slices are the option of cryopreservation, longer cell viability and possibility of 
induction studies.  Nonetheless, cryopreserved primary hepatocytes are 
challenging to work with, as experienced during the course of this PhD project.  
The culture plates need to be adequately coated with collagen matrix and extra 
care needs to be taken during media change to ensure that the collagen sheet 
with cells is not disturbed.  During the initial 48 hrs after seeding, there should 
be minimum disturbance to the culture dish so as to allow the cells to attach and 
spread out.  Although cell seeding protocol was closely adhered to, the 
hepatocytes were sensitive to handling stress during culture procedures which 
could affect its attachment ability.  The hepatocytes either remained suspended 










   50 µm 
Fig. 5-1. Cryopreserved primary human hepatocytes.   
(A) 48 hr after seeding, (B) 60 hr after seeding, some cells were still in 
suspension or did not spread out totally, (C) 5 days after seeding, clusters of 




5.1.4. Cell lines 
Immortalised cell lines for biotransformation studies can be derived from 
primary tumours of the liver parenchyma or transfecting cell lines to 
overexpress cytochrome enzymes.  The well characterised human hepatoma cell 
line, HepG2, is the most widely use tumour-derived cell line. However, under 
standard culturing conditions, it has low expression or absence of most 
important phase I and phase II drug-metabolising enzymes.  Although 
expression of cytochrome isoforms such as CYP1A and 3A can be increased in 
the presence of inducing agents, the overall cytochrome activity is still relatively 
low.  Other hepatoma cell lines that are available commercially include SNU, 
Hep 3B, HepG2/C3A, PLC/PRF/5 (www.atcc.org).  Six different clones of SNU 
were isolated from primary tumours of Korean patients [168].  These cells were 
characterised and proposed as in vitro model for studying human hepatocellular 
carcinoma.  To date, the biotransformation abilities of these 6 cell lines have not 
been studied.  Moreover, hepatitis B virus DNA was found integrated in the 
genomes of all the cell lines.  Hence its application in drug biotransformation 
studies is improbable.  HepG2/2.2.1 and HepG2/C3A were both derived from 
HepG2, where HepG2/2.2.1 were transfected with a human cholesterol 7 alpha-
hydroxylase minigene/Luciferase construct, and HepG2/C3A is a HepG2 clone 
that was selected for strong contact inhibition growth, high albumin production, 
high production of AFP and ability to grow in glucose deficient medium.  In a 
recent report, it was found that the presence of insulin and varying the 
concentration of glucose in culture medium influenced HepG2/C3A cell 
metabolism [169].  Hence further optimization of culture condition and 
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characterization is needed to establish HepG2/C3A as an alternative to primary 
hepatocytes.   
HepaRG™ cells, the latest cell line product from Invitrogen™, is 
marketed to have high levels of both phase I and II drug-metabolizing enzymes 
and active drug transporters with intact nuclear receptors pathways. The product 
has a limited use license, restricting it for research use only.    Users are also 
instructed to consider the cells as a single-use, disposable product that must be 
destroyed upon conclusion of an experiment.  This would translate to high cost 
of the HepaRG™ cells, making it less attractive for large scale research and 
preclinical applications. 
 
Immortalized normal human hepatocytes are commercially available as 
THLE-2 and THLE-3 cell lines.  These cell lines were derived by infecting 
primary normal hepatocytes with the simian virus 40 large T antigen [170].  The 
cells were found to be able to metabolise chemical carcinogens, and in early 
passage, expressed hepatic marker, KRT18 and secreted albumin.  However, at 
higher passage, the cells started to express KRT19 and decreased albumin 
secretion, indicating dedifferentiation of the cells.  Dedifferentiation of these 
THLE cells at high passage unavoidably raises the question if metabolic 
functions of these cells will be compromised and hence diminished its 
application as alternative to primary human hepatocytes for in vitro drug 




5.1.5. Differentiated progenitor cells 
Each in vitro system has its limitations such as low expression of 
cytochrome P450 enzymes and inconsistent supply of hepatocytes with stable 
characteristics for large-scale, high-throughput applications.  Therefore there is 
a need to search for alternative in vitro drug biotransformation systems.  The 
advantages of umbilical cord progenitor cells have been reviewed in earlier 
chapters, and its ability to differentiate into hepatocyte-like cells is illustrated in 
Chapter 4.  Due to different translation rates, mRNA and enzyme stabilities, 
data from RT-PCR experiment may not always reflect the concentrations of 
catalytically active enzymes present in cells [171, 172].  Therefore we 
endeavored to evaluate the functional metabolic abilities of the HLCs, using 
ultra performance liquid chromatography coupled with the 3200 QTrap mass 
spectrometer (UPLC/MS/MS) that is equipped with triple quadrupole/linear ion 








 Luminescent cell viability assay kit was from Promega 
(Madison, WI, USA).  6β-hydroxytestosterone (6β-OHT) and 4-
hydroxydiclofenac (4-OHDf) drug reference standards were from Cerilliant (TX, 
USA), while 2α-hydroxytestosterone (2α-OHT), 15β-hydroxytestosterone (15β-
OHT), and 16β-hydroxytestosterone (16β-OHT) were from Steraloids Inc 
(Newport, RI, USA).  Diclofenac, phenacetin, 4-acetamidophenol (APAP), 
flufenamic acid, salicylamide, carbamazepine and promethazine HCl were from 





 MAX, and Oasis
®
 WCX) were purchased from 
Waters (Milford, Massachusetts, USA).  All chemical solvents were from Merck 
unless otherwise stated.  Sources for culture media, NHeps and HepG2 cells 
were as stated under “Materials” of Chapter 4. 
 
 
5.2.2. Method and instrumentation 
5.2.2.1. Drug incubation 
Cells were cultured in 24-well plates.  UCLECs from three different 
umbilical cords were randomly selected from the specimen bank of 
CellResearch Corporation, Singapore, and were subjected to hepatic 
differentiation as stated in Chapter 4: Methods.  NHeps and HepG2 cell line 
were included in the assay for comparison.  Culturing procedures were as stated 
in Chapter 4: Methods.  On Day 28 of differentiation, assay for functional 
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activities of three major cytochrome P450 enzymes: CYP1A2, CYP2C9, and 
CYP 3A4 was performed using FDA-preferred drug substrates.  All culture 
media were removed and replaced with DMEM without phenol red, containing 
drug substrates to the tested.  Each well of HLCs, NHeps and HepG2 were 
incubated with 500 µl of media separately containing either vehicle blank or 25 
µM drug substrates, at 37
o
C in an atmosphere of 95% air and 5% carbon dioxide.  
After 4 hr, an aliquot of 200 µl of the medium was taken from each well and 
added to 400 µl of acetonitrile (ACN) containing respective internal standards to 
stop further enzymatic reactions.  Each set of experiment was carried out in 
triplicates. 
 
5.2.2.2. Cell viability assay 
As it is impossible to seed the same amount of NHeps and HepG2 as 
HLCs in each well, the CellTiter-Glo
®
 Luminescent cell viability assay was 
used to normalise the results for fair comparison among the three different in 
vitro systems.  After the aliquot was removed for detection of metabolites, a 
volume of CellTiter-Glo Reagent equal to the remaining 300 µl of medium in 
each well was added in accordance to the manufacturer’s protocol.  Luminescent 







5.2.2.3. Sample clean-up: Solid Phase Extraction (SPE) 
In order to increase concentration of the metabolites for detection on the 
UPLC/MS/MS, samples were concentrated.  However, salts and other 
interfering components present in the samples were also concentrated.  High salt 
content is known to cause ion suppression in electrospray ionization mass 
spectrometry.  Hence clean-up of the samples before injecting into the 
UPLC/MS/MS was necessary to reduce the interference from background noise.  
The medium-ACN mixture collected after drug incubation was centrifuged at 13, 
000 rpm for 20 min, followed by transfer of the clear supernatant to a new 
microtube and diluted with 1200 µl of milliQ water. In accordance to the 
chemical properties of each drug substrate, sample mixtures were subjected to 
solid phase extraction using either Oasis
®
 HLB or Oasis
®
 MAX solid phase 
extraction cartridges.   
 
Choice of Solid Phase Extraction cartridges 
Oasis
®
 HLB is a reversed-phase SPE cartridge, containing strongly 
hydrophobic, water-wettable polymer with hydrophilic-lipophilic balance.  
Therefore it retained carbamazepine, testosterone and its metabolites on the 
sorbent, separated from salts in the cell culture media.  Oasis
®
 MAX is a mixed 
mode phase SPE cartridge.  The water-wettable polymer is stable from pH 0 to 
14 with selectivity and sensitivity for acidic compounds through strong anion-
exchange and reversed-phase retention mechanism.  Phenacetin, APAP, 
salicylamide, flufenamic acid, diclofenac and hydroxydiclofenac are acidic and 





The solid phase extraction general procedure was the same for all 
samples (Fig. 5-2), but the solvents used were changed in accordance to the 
requirement of the drug substrates and cartridges.  An exception was made for 
samples containing phenacetin, where sample mixtures were adjusted to 
approximately pH 12 with ammonia water before loading into SPE cartridges. 
All eluents were dried at 37
o
C under nitrogen stream, and reconstituted to 50 µl 
with solvent mixtures as stated in Table 5-1.  Finally, 2 µl of each sample was 





Fig. 5-2. General SPE protocol for sample preparation before injection into 
UPLC/MS/MS.   
Cartridges used were 1 ml in volume, containing 30 mg of sorbent material. 
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Table 5-1. Solvent for respective SPE cartridges. 
 
ACN: acetonitrile, EtOAc: ethyl acetate, EtOH: ethanol, H2O: milliQ water, IPA: isopropanol, 
MeOH: methanol, NH3: ammonia solution.  Eluents were collected and dried under 
nitrogen stream at 37
o
C.  Eluents 1 and 2 for APAP sample were combined in 




Table 5-2. Drug substrates for respective cytochrome P450 isozymes. 
CYP450  Internal Standard Drug Substrate Metabolite 
1A2  Salicylamide Phenacetin APAP 
 m/z 138→120.9 180→110 152→110 
 
CE 







2C9  Flufenamic acid Diclofenace 4OH Diclofenac 




-25 -17.5 -18 
     
3A4  Carbamazepine Testosterone 2αOH Testosterone 
 m/z 237→194.2 289→97 305→269.3 
 
CE 
(V) 26 28 21.5 
    
 
  
(Table continues next page) 
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CYP450  Internal Standard Drug Substrate Metabolite 
  Carbamazepine Testosterone 6βOH Testosterone 
3A4 m/z 237→194.2 289→97 305→269.3 
 
CE 
(V) 26 28 30 
     
     
     
    15βOH Testosterone 
 m/z   305→97.3 
 
CE 
(V)   40 
     
     
     
    16βOH Testosterone 
 m/z   305→97.3 
 
CE 
(V)   37 
     
The mass transition and collision energy (CE) used for detecting each drug 






UPLC/MS/MS instrument and conditions 
The chromatographic system used was the Waters Acquity UPLC
®
 
system with Acquity UPLC
®
 BEH C18 column (1.7 µm particle size, 100 x 2.1 
mm i.d.), operated at 45
o
C, 0.5 ml/min flow rate.  The gradient used is as 
indicated in Table 5-3.  Mobile phase A was MilliQ water with 0.1% v/v formic 
acid, and mobile phase B was acetonitrile with 0.1% v/v formic acid. 
 




Phenacetin Diclofenac Testosterone 
0.00 90 60 78 
2.40 80 15 30 
2.41 5 5 5 
2.99 5 5 5 
3.00 90 60 78 
4.00 90 60 78 
Concentration gradient of mobile phase A used for running of UPLC system for 
respective drug substrates and corresponding hydroxylated metabolites. 
 
The AB Biosystem Qtrap 3200 MS/MS triple quadrupole mass 
spectrometer was used for detection of the metabolites, operating in the multiple 
reaction monitoring (MRM) positive ionization mode for detection of 
phenacetin, testosterone metabolites, and negative mode for detection of 
diclofenac metabolite.   
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Quantification of the metabolites was performed using the Analyst 
software.  As cell numbers in different in vitro system vary, peak intensities 
quantified by Analyst were normalised using CellTiter-Glo® Luminescent Cell 
viability assay for unbiased comparison of metabolite concentration. 
 
5.2.2.5. SPE method evaluation 
Percentage recovery of analytes in samples after SPE treatment was 
assessed to ensure absence of metabolites was due to lack of biotransformation 
of the drug substrates by the cells and not loss through SPE process.  Respective 
metabolite standards were prepared and divided into 2 portions.  The first 
portion was subjected to SPE treatment as illustrated in Fig 5-2. After which, 
respective internal standards were added to eluents prior to drying under 
nitrogen stream.  The second portion was subjected to the same procedure 
without SPE treatment.  Dried samples were reconstituted, and 2 µl of each 
sample was injected into UPLC/MS/MS for analysis.  Mean relative recovery of 
each analyte that went through solid phase extraction was calculated against the 
mean recovered concentration of analyte that did not undergo solid phase 
extraction. 
 
5.2.2.6. Calibration curve for 6β-hydroxytestosterone 
Carbamazepine was used as internal standard.  Stock solutions of 6β-
hydroxytestosterone and carbamazepine were prepared using methanol as 
solvent. Solvent for subsequent dilution was a mixture of methanol and MilliQ 
water at ratio of 1:1.  For calibration of 6β-hydroxytestosterone, the following 
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concentrations were prepared: 0.0 µM, 0.025 µM, 0.05 µM, 0.10 µM, 0.25 µM, 
0.50 µM, 1.00 µM, 2.50 µM, and 5.00 µM.  The concentration of 
carbamazepine was maintained at 0.25 µM in all samples.  Sample volume of 2 
µl was injected into the UPLC/MS/MS for analysis, and triplicate sampling was 





5.3. Results  
5.3.1. SPE method evaluation 
Table 5-4. Mean recovery of analyte after SPE treatment. 
Analyte Mean Recovery (%) SD 
APAP 72.0 9.0 
OH-Diclofenac 86.9 9.1 
OH-Testosterone 93.8 6.4 
 
Percentage recovery of each analyte was calculated as concentration of analyte 
extracted from SPE against the concentration of analyte that was not subjected 
to extraction.  Assay of each analyte was performed in triplicate. 
 
 
5.3.2. CYP 1A2: Phenacetin metabolism 
UPLC/MS/MS performed using reference drug standard, 4-
acetamidophenol, showed that the chromatographic peak for the hydroxylated 
metabolite of phenacetin was expected at the retention time of 1.10 min for mass 
transition m/z 152 → 110. When reconstituted samples were delivered into the 
UPLC/MS/MS, APAP chromatographic peak was detected in NHeps at 
retention time of 1.10 min (Fig. 5-3).  Mean normalised concentration of APAP 
formed was calculated to be 0.104 ± 0.029 pM. The metabolite was undetected 








Fig. 5-3. Extracted ion chromatographs of APAP in respective cell systems. 
Peak for APAP was detected only in NHeps at retention time 1.10 min. 
? : missing APAP peak. 
NHeps 




5.3.3. CYP 2C9: Diclofenac metabolism 
At mass transition m/z 311.8 → 267.7, the metabolite 4-
hydroxydiclofenac was detected at retention time of 1.41 min for NHeps (Fig. 5-
4), at mean normalised concentration of 0.118 ± 0.021 pM.  Although peaks 
were detected at 1.41 min for both Day 28 HLCs and HepG2 systems, 
quantitation of the chromatograms by the Analyst programme revealed that the 
analyte peak area counts were zero.  Therefore the peaks observed for Day 28 


















Fig. 5-4. Extracted ion chromatographs of 4-hydroxydiclofenac in 
respective cell systems.  





5.3.4. CYP 3A4: Testosterone metabolism 
All three in vitro cell systems were able to metabolize testosterone to its 
hydroxylated metabolites (Fig. 5-5).  Four chromatographic peaks were detected 
in Day 28 HLCs samples.  For mass transition m/z 305 → 269.3, two metabolite 
peaks were detected.  At retention time of 1.52 min, the peak was identified to 
be 6β-OHT.  At retention time of 1.92 min, the peak was identified to be 2α-
OHT.  For mass transition m/z 305 → 97.3, the two metabolite peaks detected 
were identified to be 15β-OHT at 1.45 min and 16β-OHT at 1.84 min.  Only two 
chromatographic peaks were detected in both NHeps and HepG2 samples, 
namely for 6β-OHT and 15β-OHT.  Mean concentration of 6β-OHT formed by 
HLCs, NHeps and HepG2 were calculated to be 0.062 ± 0.034 pM, 0.211 ± 
0.070 pM, and 0.007 ± 0.011 pM respectively (Fig. 5-6).  Details of calibration 
results can be found in appendix 3-1 and 3-2, while details of 6β-





Fig. 5-5. Extracted ion chromatographs of hydroxytestosterone isomers in 
respective cell systems. 
Respective retention time: 2α-OHT at 1.92 min, 6β-OHT at 1.52 min, 15β-OHT 




Fig. 5-6. Concentration of 6β-OHT formed by 3 different in vitro systems.   
Data from Analyst programme was normalized using CellTiter-Glo® 
Luminescent cell viability assay for unbiased comparison. Chart values are 
plotted based on (mean ± SD) pM, n  3.  Normalised mean concentration of 
6β-OHT formed by HLCs, NHeps and HepG2 were calculated to be 0.062 ± 
0.034 pM, 0.211 ± 0.070 pM, and 0.007 ± 0.011 pM respectively.  Three of the 
five samples for HepG2 had undetectable chromatogram peaks which were 










5.4.  Discussion 
Liquid chromatography coupled with mass spectrometry is a common 
method employed in drug metabolism studies.  However, matrix interference 
and suppression are some of the limitations of this sensitive analytical method.  
Though the acetonitrile added to medium aliquots at the end of drug incubation 
experiment terminates all enzymatic reactions and removes proteinaceous 
interferences, salts from the culture media still remain in the samples.  When the 
amount of analyte is low, concentration of samples is required for detection.  
However background interferences are augmented in face of concurrent 
concentration of salts.    More cells would be needed to metabolize drug 
compounds to a detectable quantity if concentration of samples is not performed.  
In our study the medium aliquots were subjected to clean-up using SPE prior to 
UPLC/MS/MS analysis.  To the best of our knowledge, this is the first report of 
an analytical method combining SPE with UPLC/MS/MS for detection of 
metabolites in culture media as an indication of metabolic functionality of stem 
cells-derived HLCs.  The additional SPE procedure reduces ion suppression and 
background interference by separating salts from the analyte before 
concentrating the samples, and hence improves detection sensitivity by the mass 
spectrometer without the need for large amount of cells.   
 
With cross-reference to RT-PCR results of the cytochrome P450 
enzymes in Chapter 4, the substantial band intensity of CYP1A2 gene for Day 
28 HLCs and HepG2 should be an indicator of detecting metabolism of 
phenacetin to APAP in this functionality assay.  However, the result of the 
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present study was the contrary.  The lack of CYP1A2 functionality in Day 28 
HLCs could be due to the lack of essential coactivators to activate its function.  
The steroid receptor coactivator (SRC) gene family contains three homologous 
members that serve as transcriptional coactivators for nuclear receptors and 
other transcription factors [144].  In the review by Castell and co-workers, it 
was reported that transfection of SRC-1 coactivators in HepG2 cells caused a 
significant transactivation of the HNF4-regulated CYP2C9 [141].  Hence it is 
highly possible that there is a lack of essential coactivators for the activation of 
CYP1A2 function in Day 28 HLCs and HepG2.  On the other hand, the absence 
of hydroxydiclofenac in HepG2 and Day 28 HLCs is not surprising as gene 
expression for CYP2C9 was hardly detectable in HepG2 and not detected in 
Day 28 HLCs as reported in Chapter 4.   
 
The presence of CYP3A4 activity is an essential necessity as CYP3A4 is 
one of the major contributors to metabolic activities in liver [173].  Testosterone 
was the selected drug substrate due to its high correlation for CYP3A4 activity 
[174] and also a US FDA-preferred chemical substrate for in vitro drug 
development experiments involving CYP3A4.  Our HLCs data concurred with a 
development and partial validation report of using UPLC/MS/MS method for 
determination of testosterone and its metabolites in cryopreserved human 
hepatocytes [175].  Wang’s group reported that the UPLC/MS/MS is a fast, 
sensitive and specific method for separating and identifying testosterone and its 
chemically similar metabolites, and the metabolites were best separated using 
Acquity UPLC
®
 C18 column.  However, in our study the 2α-OHT and 16β-OHT 
metabolites were detected in HLCs but not in NHep.   
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It was reported that even when well-defined freeze-thaw conditions were 
adhered to, the viability of hepatocytes and attachment efficiency declined after 
cryopreservation [162, 176].  In addition, there is a marked down-regulation of 
most cytochrome P450 gene transcripts upon plating of the primary hepatocytes 
relative to freshly isolated primary hepatocytes.  During cell plating in our study, 
there was a significant amount of hepatocytes remaining in suspension after the 
48-hr recovery and adherence allowance.  Hence the absence of 2α-OHT and 
16β-OHT in NHeps of our study could be due to insufficient enzyme isoforms 
for 2α- and 16β-hydroxylation as a result of decrease cell viability, or alterations 
in the CYP3A4 gene transcription during freeze-thaw and cell plating 
procedures.    
 
After normalization against cell viability, our data showed that NHeps is 
the most ideal in vitro system for metabolism based on the much higher 6β-OHT 
concentration detected.  An expected observation which is in-line with the 
unanimous acceptance of NHeps as the gold standard for in vitro drug studies 
model.  The HLCs metabolism of testosterone to 6β-OHT was approximately 29% 
that of NHeps.  Although metabolic abilities of the HLCs were not as competent 
as desired, it is unquestionably a better performance than HepG2 of only 
approximately 3% of NHeps.  In addition, it was noted that of the five HepG2 
samples that were analysed for presence of 6β-OHT, the metabolite was not 
detectable in three samples.  As the cytochrome enzyme activity in HepG2 is 
low and it is tumorigenic, further development of this cell line for clinical use is 
regarded as unachievable at this point.    
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  It has been shown that sandwich-culture configuration of isolated 
hepatocytes between ECM such as collagen resulted in reestablishment of 
matured hepatocyte functions, including transporter activities [177, 178], which 
is more reflective of in vivo pharmacodynamics.  Therefore sandwich-culture 
configuration would usually be recommended for studies involving NHeps.  
However, it is in the interest of this project to investigate the intrinsic metabolic 
abilities of the HLCs.  Hence there was no layering of ECM onto the UCLECs 
during differentiation to exclude additional variables from the possibility of 
transporters establishment, and the NHeps used in our study were not cultured in 
the sandwich-culture configuration for fair comparison among the in vitro 
systems.  Although differentiation was carried out in the absence of exogenous 
ECM or 3-D structures, our results showed that the CYP3A4 enzyme of HLCs 
possessed intrinsic enzymatic activity ≈29% that of NHeps.  This encouraging 
finding signifies that future hepatic differentiation of the UCLECs in sandwich-
culture configuration concurrently with 3D co-culture with other accessory liver 
cells would potentially stimulate an increase in CYP3A4 activity of HLCs to a 
level that could be adequate for scale-up and application in high throughput drug 
screening platform. 
 
The lack of functional activity of CYP1A2 enzyme despite gene 
expression of the cytochrome requires further investigation, which is not within 
the resources of our project.  In summary, this study showed that the CYP3A4 
enzyme present in HLCs is functionally active and there is optimistic prospect 
of developing the HLCs further for use with high throughput drug screening 
platform.    
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CHAPTER 6: CONCLUSIONS 
6.1. Potential of ALCs in in vitro studies and clinical applications 
In vitro differentiation of ASCs into terminal cells of the three germ 
layers is not new.  However, the ASCs are usually obtained from bone marrow.  
As mentioned in Chapter 1, invasive surgery is required to harvest ASCs from 
bone marrow, which inevitably deters many from making tissue donation as it 
poses some extent of surgical risk and inconvenience to the donors.  Another 
extensively studied ASC source is the adipose tissue.  Adipose-derived 
mesenchymal stem cells are able to differentiate into many different cell types 
of mesodermal lineages.  Similar to bone marrow, the harvest of adipose tissues 
requires invasive surgery.  Liposuction is usually carried out for cosmetic 
reasons and it is impractical to depend on such elective surgery for a consistent 
supply of adipose tissues.  Furthermore quality and quantity of the ASCs 
isolated from the bone marrow is affected by the donor’s age [38].  The supply 
of ASCs available for large-scale research and clinical applications will be 
limited. 
 
On the other hand, umbilical cords are easily available with less 
bioethical concerns as termination of life is not involved.  After delivery of the 
baby, the umbilical cord is usually discarded as biowaste.  Hence, the umbilical 
cord can be placed into a collector containing the required transport medium 
until subsequent harvesting of progenitor cells.  Thus it would be relatively easy 
to obtain parental consent to donate their newborn’s umbilical cord as there is 
neither additional distress nor inconvenience to the mother and baby.   
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The physical and psychological impediments of obesity, coupled with its 
social stigma are driving many individuals to seek ways to prevent or shed 
excess weight.  It also causes abnormalities in the endocrine system and 
consequently an adverse bearing on reproduction.  As the penchant to 
overindulge and revel in a sedentary lifestyle becomes more prevalent with the 
growing affluence of developing countries, obesity and other related diseases 
are mounting health concerns.  The exact molecular and cellular involvements in 
the development of obesity and related metabolic diseases remain to be 
elucidated.  The work in chapter 3 illustrates for the first time the ability of 
UCLMCs to differentiation into ALCs and could potentially provide an in vitro 
model for studying pathology of obesity and related metabolic diseases. 
 
6.2. Potential of HLCs in in vitro studies and clinical applications 
Preclinical drug metabolism studies to determine the efficacies and 
toxicities of new drug entities ensure the safety of consumers.  Primary cultured 
hepatocytes, liver slices, microsomes and hepatic cell lines such as HepG2, BC2 
and HepaRG, have been used for in vitro drug metabolism studies.  However the 
shortage of the liver organ, high batch-to-batch functional variability of 
hepatocytes from different liver donors, and low or partial expressions of 
relevant cytochrome P450 metabolising enzymes in cell lines demand 
alternatives [152].  Human umbilical cords will provide ample supply of 
progenitor cells for large-scale research purposes and clinical applications.  The 
advantages of not having to wrestle with ethic committees and avoiding the 
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hassle of translating cross species differences from animal work to human 
models help to hasten the move from bench top to bedside.   
 
The studies in Chapter 4 and 5 showed that multipotent UCLECs can 
differentiate into HLCs with potential to serve as a novel cell source for in vitro 
drug metabolism studies, as well as to be developed into models of liver 
diseases.   
 
In summary, our research has yielded the following novel observations 
and findings: 
 Umbilical cord lining stem cells are an excellent cell source for in vitro 
models and have potential applications in cell-base therapy. 
 
 Obesity and normal-weight in vitro models can be created through 




 Differentiation of UCLECs to HLCs closely resembles in vivo 




 First report of incorporating SPE procedure during sample preparation of 
culture media to improve metabolite detection by UPLC/MS/MS without 






CHAPTER 7: FUTURE DIRECTIONS 
7.1. 3-Dimensional cultures  
It has been demonstrated that 3-dimensional cultures enhanced 
differentiation of progenitor cells to hepatocytes, as well as improving the 
maintenance of cellular morphology and functions [179-181].  This is due to the 
closer resemblance to the in vivo milieu, where multi-dimensional cell-to-cell 
interacts for biochemical signaling.  Therefore further development of UCSCs 
could head towards the direction of 3-dimensional culture using biocompatible 
membranes co-cultured with other accessory cells e.g. endothelial cells and 
culture media perfusion platform to better mimic in vivo milieu.  The interplay 
of biochemical signals among different cell types may enhance or suppress 
cellular responsiveness.  The 3-D co-culture setup can potentially enhance 
differentiation of UCSCs for pharmaceutical and clinical applications and also 
aid in the study of cellular development and pathology.   
 
7.2. Research on metabolic enzymes & drug transporters  
In order to attain a greater understanding of drug biotransformation, studies 
to determine the presence and functional abilities of phase II metabolism 
enzymes and drug transporters in HLCs can be carried out.  In addition, enzyme 
induction studies can be performed to assess the responsiveness of the enzymes 
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LGLI: Low Glucose Low Insulin, LGHI: Low Glucose High Insulin, HGLI: 
High Glucose Low Insulin, HGHI: High Glucose High Insulin.  C23, C31, C35 
are labelling for three different umbilical cords.  Each cord sample has triplicate 
readings, labelled as a, b and c.  Relative band intensities were calculated as the 
gene of interest-to-GAPD signal intensity ratio.    
Cord 
sample 











C23a 0.045 0.554 0.393 0.090 0.105 
C23b 0.000 0.291 0.486 0.325 0.038 
C23c 0.096 0.020 0.126 0.380 0.052 
C31a 0.000 0.253 0.162 0.190 0.483 
C31b 0.266 0.062 0.052 0.079 0.465 
C31c 0.059 0.183 0.140 0.167 0.158 
C35a 0.090 0.515 0.300 0.701 0.130 
C35b 0.160 0.059 0.000 0.015 0.086 
C35c 0.211 0.146 0.057 0.249 0.267 
Mean 0.103 0.231 0.191 0.244 0.198 
SEM 0.031 0.065 0.055 0.069 0.057 
Cord 
sample 











C23a 0.052 0.465 0.113 0.202 0.222 
C23b 0.175 0.150 0.117 0.316 0.212 
C23c 0.203 0.416 0.467 0.122 0.129 
C31a 0.116 0.653 0.551 0.682 0.554 
C31b 0.409 0.265 0.206 0.208 0.543 
C31c 0.092 0.512 0.704 0.544 0.306 
C35a 0.003 0.736 0.921 0.744 0.572 
C35b 0.149 0.105 0.132 0.061 0.272 
C35c 0.179 0.398 0.340 0.254 0.231 
Mean 0.153 0.411 0.395 0.348 0.340 
SD 0.039 0.071 0.096 0.082 0.057 
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LGLI: Low Glucose Low Insulin, LGHI: Low Glucose High Insulin, HGLI: 
High Glucose Low Insulin, HGHI: High Glucose High Insulin.  C23, C31, C35 
are labelling for three different umbilical cords.  Each cord sample has triplicate 
readings, labelled as a, b and c.  Relative band intensities were calculated as the 































C23a 0.026 0.134 0.289 0.652 0.655 
C23b 0.167 0.264 0.693 0.634 0.526 
C23c 0.197 0.557 0.567 0.293 0.344 
C31a 0.198 0.759 0.712 0.721 0.535 
C31b 0.361 0.310 0.379 0.306 0.590 
C31c 0.244 0.649 0.910 0.567 0.282 
C35a 0.000 0.550 0.206 0.413 0.628 
C35b 0.096 1.385 1.050 0.926 0.596 
C35c 0.071 0.252 0.537 0.528 0.621 
Mean 0.151 0.540 0.594 0.560 0.531 
SD 0.038 0.126 0.093 0.068 0.044 
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C23a 0.000 1.133 0.782 0.973 0.781 
C23b 0.386 0.657 0.882 0.872 0.727 
C23c 0.059 0.928 0.808 0.685 0.107 
C31a 0.446 0.776 0.810 0.948 0.881 
C31b 0.028 0.787 0.972 1.445 0.795 
C31c 0.000 0.932 0.910 0.981 0.984 
C35a 0.021 0.125 0.167 0.075 1.128 
C35b 0.000 1.051 0.858 0.984 0.943 
C35c 0.223 0.767 0.973 0.749 0.884 
Mean 0.129 0.795 0.796 0.857 0.803 
SEM 0.059 0.098 0.082 0.121 0.096 
 
LGLI: Low Glucose Low Insulin, LGHI: Low Glucose High Insulin, HGLI: 
High Glucose Low Insulin, HGHI: High Glucose High Insulin.  C23, C31, C35 
are labelling for three different umbilical cords.  Each cord sample has triplicate 
readings, labelled as a, b and c.  Relative band intensities were calculated as the 
gene of interest-to-GAPD signal intensity ratio.   
Cord 
sample 











C23a 0.086 0.857 0.906 0.653 0.670 
C23b 0.434 1.057 0.814 0.713 0.733 
C23c 0.011 0.753 0.983 0.884 0.033 
C31a 0.140 0.869 0.755 0.749 1.417 
C31b 0.187 0.773 0.770 0.805 1.017 
C31c 0.187 0.888 0.806 0.692 1.165 
C35a 0.092 0.057 0.057 0.089 0.056 
C35b 0.050 0.796 0.764 0.799 0.862 
C35c 0.060 0.497 0.678 0.656 0.780 
Mean 0.138 0.727 0.726 0.671 0.748 
SEM 0.042 0.097 0.089 0.077 0.154 
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C23a 0.000 1.040 1.042 1.228 1.771 
C23b 0.189 0.930 1.266 1.183 1.182 
C23c 0.045 1.190 1.456 0.985 0.320 
C31a 0.123 1.042 1.079 1.024 0.942 
C31b 0.214 0.929 0.903 0.918 0.856 
C31c 0.329 1.190 1.346 0.847 1.140 
C35a 0.017 0.976 0.964 0.910 2.528 
C35b 0.000 0.182 0.160 0.273 1.005 
C35c 0.095 1.608 1.050 0.975 0.850 
Mean 0.112 1.010 1.030 0.927 1.177 
SEM 0.038 0.125 0.125 0.092 0.211 
 
 
LGLI: Low Glucose Low Insulin, LGHI: Low Glucose High Insulin, HGLI: 
High Glucose Low Insulin, HGHI: High Glucose High Insulin.  C23, C31, C35 
are labelling for three different umbilical cords.  Each cord sample has triplicate 
readings, labelled as a, b and c.  Relative band intensities were calculated as the 














Appendix 2. Content of hepatic differentiation media from Lonza. 
 
HCM™ BulletKit®  
Contents:  
• 500ml of Hepatocyte Basal Medium (HBM™)  
• HCM™ SingleQuots® 





• Epidermal growth factor (human, recombinant) 
• Ascorbic acid 
• Transferrin 
• Hydrocortisone 21 hemisuccinate 
• Insulin (human, recombinant) 
• Gentamicin sulphate, amphotericin-B 










• Gentamicin sulphate, amphotericin-B 
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Appendix 3-1. Calibration results of 6β-hydroxytestosterone. 
 
Each concentration was carried out in triplicate as indicated by number suffix at 
the end of each sample name.  Carbamazepine was used as internal standard (IS), 
and concentration was maintained at 0.25 µM for all the samples.  Calculated 
concentration of 6β-hydroxytestosterone and accuracy of sample preparation 
were generated by the Analyst software.  Readings which fall within the 
accuracy percentage range of 85% to 125% were selected, as indicated by “”, 
















 0µM -1   0.00 1.08e+005 No Peak N/A  
 0µM -2   0.00 1.00e+005 No Peak N/A  
 0µM -3   0.00 8.96e+004 No Peak N/A  
 0.025µM -1   1.73e+002 8.21e+004 0.0284 113.0  
 0.025µM -2   2.08e+002 8.85e+004 0.0316 126.0 - 
 0.025µM -3   1.82e+002 8.04e+004 0.0304 122.0  
 0.05µM -1   3.72e+002 7.32e+004 0.0686 137.0 - 
 0.05µM -2   3.47e+002 6.84e+004 0.0684 137.0 - 
 0.05µM -3   3.35e+002 6.48e+004 0.0698 140.0 - 
 0.10µM -1   5.67e+002 6.30e+004 0.121 121.0  
 0.10µM -2   5.32e+002 6.01e+004 0.119 119.0  
 0.10µM -3   5.32e+002 5.99e+004 0.120 120.0  
 0.25µM -1   1.37e+003 5.18e+004 0.357 143.0 - 
 0.25µM -2   1.18e+003 5.25e+004 0.302 121.0 - 
 0.25µM -3   1.46e+003 5.20e+004 0.379 152.0 - 
 0.5µM -1   2.11e+003 5.37e+004 0.529 106.0  
 0.5µM -2   1.80e+003 5.08e+004 0.477 95.4  
 0.5µM -3   2.06e+003 5.12e+004 0.543 109.0  
 1.00µM -1   3.67e+003 4.66e+004 1.06 106.0  
 1.00µM -2   3.64e+003 4.65e+004 1.05 105.0  
 1.00µM -3   3.40e+003 4.35e+004 1.05 105.0  
 2.50µM -1   8.60e+003 4.38e+004 2.65 106.0  
 2.50µM -2   8.15e+003 4.35e+004 2.53 101.0  
 2.50µM -3   8.61e+003 4.08e+004 2.84 114.0  
 5.00µM -1   1.52e+004 4.15e+004 4.95 99.0  
 5.00µM -2   1.48e+004 4.03e+004 4.95 99.0  
 5.00µM -3   1.36e+004 4.27e+004 4.30 85.9  
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Appendix 3-2. Calibration curve of 6β-hydroxytestosterone. 
 
y = 0.0742x + 3.14e-7 
r = 0.9966 
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 397960 0.1658 
0.211 0.070 NHep_2 8.17 x 10
-8
 462790 0.1766 
NHep_3 1.31 x 10
-7
 447270 0.2918 
HepG2_1 1.10 x 10
-8
 428582 0.0257 
0.007 0.011 
HepG2_2 No peak 361312 0.0 
HepG2_3 No peak 382190 0.0 
HepG2_4 No peak 378162 0.0 
HepG2_5 3.68 x 10
-9
 432610 0.0085 
HLC_1 1.09 x 10
-7
 2554549 0.0427 
0.062 0.034 
HLC_2 1.93 x 10
-7
 2556649 0.0754 
HLC_3 1.82 x 10
-7
 2951849 0.0616 
HLC_4 2.73 x 10
-7
 3633000 0.0750 
HLC_5 2.34 x 10
-7
 3443100 0.0680 
HLC_6 3.18 x 10
-7
 2837900 0.1119 
HLC_7 5.73 x 10
-9
 3606000 0.0016 





Appendix 5-1. Representative of overlayed ion chromatograph of hydroxytestosterone and carbamazepine in Day 28 HLCs.
Carbamazepine, 
R.T. = 1.88mins 
2α-OHT,           
R.T. = 1.92 mins  
16β-OHT, 
R.T. = 1.84mins 
6β-OHT         
R.T. = 1.52mins 
15β-OHT         
R.T. = 1.45mins 
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Appendix 5-2. Representative of overlayed ion chromatograph of hydroxytestosterone and carbamazepine in NHeps. 
Carbamazepine, 
R.T. = 1.87mins 
6β-OHT         
R.T. = 1.52mins 
15β-OHT         
R.T. = 1.45mins 
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Appendix 5-3. Representative of overlayed ion chromatograph of hydroxytestosterone and carbamazepine in HepG2. 
Carbamazepine, 
R.T. = 1.88mins 
6β-OHT         
R.T. = 1.52mins 
15β-OHT         
R.T. = 1.45mins 
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Appendix 5-4. Representative of overlayed ion chromatograph of phenacetin metabolism in Day 28 HLCs. 
 Salicylamide was used as internal standard. 
Phenacetin,  
R.T. = 3.19mins 
Salicyclamide,  





Appendix 5-5. Representative of overlayed ion chromatograph of phenacetin metabolism in NHeps. 
Salicylamide was used as internal standard.  
Phenacetin,  
R.T. = 3.19mins 
Salicyclamide,  
R.T. = 2.24mins 
APAP,        




Appendix 5-6. Representative of overlayed ion chromatograph of phenacetin metabolism in HepG2. 
Salicylamide was used as internal standard. 
Phenacetin,  
R.T. = 3.19mins 
Salicyclamide,  




Appendix 5-7.  Representative of overlayed ion chromatograph of diclofenac metabolism in Day 28 HLCs. 
Flufenamic acid was used as internal standard. 
Flufenamic acid,  
R.T. = 2.29mins 
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Appendix 5-8. Representative of overlayed ion chromatograph of diclofenac metabolism in NHeps. 
Flufenamic acid was used as internal standard. 
Flufenamic acid,  
R.T. = 2.30mins 
4- hydroxydiclofenac,  




Appendix 5-9.Representative  of overlayed ion chromatograph of diclofenac metabolism in HepG2. 
Flufenamic acid was used as internal standard.  
Flufenamic acid,  




1. Bongso A, Fong CY, Ng SC, Ratnam S: Isolation and culture of inner 
cell mass cells from human blastocysts. Hum Reprod 1994, 9(11):2110-2117. 
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, 
Marshall VS, Jones JM: Embryonic stem cell lines derived from human 
blastocysts. Science 1998, 282(5391):1145-1147. 
3. Odorico JS, Kaufman DS, Thomson JA: Multilineage differentiation 
from human embryonic stem cell lines. Stem Cells 2001, 19(3):193-204. 
4. Zipori D: The stem state: Mesenchymal plasticity as a paradigm. Curr 
Stem Cell Res Ther 2006, 1(1):95-102. 
5. Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, 
Steward O: Human embryonic stem cell-derived oligodendrocyte progenitor cell 
transplants remyelinate and restore locomotion after spinal cord injury. J 
Neurosci 2005, 25(19):4694-4705. 
6. Ghodsizad A, Niehaus M, Kogler G, Martin U, Wernet P, Bara C, 
Khaladj N, Loos A, Makoui M, Thiele J, Mengel M, Karck M, Klein HM, 
Haverich A, Ruhparwar A: Transplanted human cord blood-derived unrestricted 
somatic stem cells improve left-ventricular function and prevent left-ventricular 
dilation and scar formation after acute myocardial infarction. Heart 2009, 
95(1):27-35. 
7. Bayes-Genis A, Soler-Botija C, Farre J, Sepulveda P, Raya A, Roura S, 
Prat-Vidal C, Galvez-Monton C, Montero JA, Buscher D, Belmonte JC: Human 
progenitor cells derived from cardiac adipose tissue ameliorate myocardial 
infarction in rodents. J Mol Cell Cardiol 2010, 49(5):771-780. 
8. D'Agostino B, Sullo N, Siniscalco D, De Angelis A, Rossi F: 
Mesenchymal stem cell therapy for the treatment of chronic obstructive 
pulmonary disease. Expert Opin Biol Ther 2010, 10(5):681-687. 
9. Davani B, Ikonomou L, Raaka BM, Geras-Raaka E, Morton RA, 
Marcus-Samuels B, Gershengorn MC: Human islet-derived precursor cells are 
mesenchymal stromal cells that differentiate and mature to hormone-expressing 
cells in vivo. Stem Cells 2007, 25(12):3215-3222. 
124 
 
10. Jiang J, Au M, Lu K, Eshpeter A, Korbutt G, Fisk G, Majumdar AS: 
Generation of insulin-producing islet-like clusters from human embryonic stem 
cells. Stem Cells 2007, 25(8):1940-1953. 
11. Fortier LA: Stem cells: Classifications, controversies, and clinical 
applications. Vet Surg 2005, 34(5):415-423. 
12. Stem Cell Basics. In Stem Cell Information 2009, accessed 8 February 
2011. Bethesda, Maryland: National Institutes of Health, U.S. Department of 
Health and Human Services, (http://stemcells.nih.gov/info/basics/defaultpage). 
13. Regenerative Medicine. Bethesda, Maryland: National Institutes of 
Health, U.S. Department of Health and Human Services; 2006. 
14. Stem Cells: Scientific Progress and Future Research Directions. 
Bethesda, Maryland: National Institutes of Health, U.S. Department of Health 
and Human Services; 2001. 
15. Malgieri A, Kantzari E, Patrizi MP, Gambardella S, Schwartz RE, Reyes 
M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, 
Verfaillie CM, Roelandt P, Pauwelyn KA, Sancho-Bru P, Subramanian K, 
Ordovas L, Vanuytsel K, Geraerts M, Firpo M, De Vos R, Fevery J, Nevens F: 
Bone marrow and umbilical cord blood human mesenchymal stem cells: State of 
the art. Int J Clin Exp Med 2010, 3(4):248-269. 
16. Charbord P: Bone marrow mesenchymal stem cells: Historical overview 
and concepts. Hum Gene Ther 2010, 21(9):1045-1056. 
17. Choumerianou DM, Martimianaki G, Stiakaki E, Kalmanti L, Kalmanti 
M, Dimitriou H: Comparative study of stemness characteristics of mesenchymal 
cells from bone marrow of children and adults. Cytotherapy 2010, 12(7):881-
887. 
18. Mareschi K, Biasin E, Piacibello W, Aglietta M, Madon E, Fagioli F: 
Isolation of human mesenchymal stem cells: Bone marrow versus umbilical 
cord blood. Haematologica 2001, 86(10):1099-1100. 
19. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, 
Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a 




20. Tuli R, Tuli S, Nandi S, Wang ML, Alexander PG, Haleem-Smith H, 
Hozack WJ, Manner PA, Danielson KG, Tuan RS: Characterization of 
multipotential mesenchymal progenitor cells derived from human trabecular 
bone. Stem Cells 2003, 21(6):681-693. 
21. Catón J, Bostanci N, Remboutsika E, De Bari C, Mitsiadis TA: Future 
dentistry: Cell therapy meets tooth and periodontal repair and regeneration. J 
Cell Mol Med 2011, 15(5):1054-1065. 
22. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, 
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of 
adult human mesenchymal stem cells. Science 1999, 284(5411):143-147. 
23. Pappa KI, Anagnou NP: Novel sources of fetal stem cells: Where do 
they fit on the developmental continuum? Regen Med 2009, 4(3):423-433. 
24. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM: Human first-
trimester fetal MSC express pluripotency markers and grow faster and have 
longer telomeres than adult MSC. Stem Cells 2007, 25(3):646-654. 
25. Boyd AS, Higashi Y, Wood KJ: Transplanting stem cells: Potential 
targets for immune attack. Modulating the immune response against embryonic 
stem cell transplantation. Adv Drug Del Rev 2005, 57(13):1944-1969. 
26. Swijnenburg RJ, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F, 
Lebl DR, Caffarelli AD, de Bruin JL, Fedoseyeva EV, Robbins RC: Embryonic 
stem cell immunogenicity increases upon differentiation after transplantation 
into ischemic myocardium. Circulation 2005, 112(9 Suppl):I166-172. 
27. Baksh D, Song L, Tuan RS: Adult mesenchymal stem cells: 
Characterization, differentiation, and application in cell and gene therapy. J Cell 
Mol Med 2004, 8(3):301-316. 
28. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, 
Koc ON: Human mesenchymal stem cells support unrelated donor 
hematopoietic stem cells and suppress T-cell activation. Bone Marrow 
Transplant 2004, 33(6):597-604. 
29. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O: HLA 
expression and immunologic properties of differentiated and undifferentiated 
mesenchymal stem cells. Exp Hematol 2003, 31(10):890-896. 
126 
 
30. Kim YJ, Broxmeyer HE: Immune regulatory cells in umbilical cord 
blood and their potential roles in transplantation tolerance. Crit Rev Oncol 
Hematol 2011, 79(2):112-126. 
31. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, 
Andreeff M, Marini FC: Reduction of nontarget infection and systemic toxicity 
by targeted delivery of conditionally replicating viruses transported in 
mesenchymal stem cells. Cancer Gene Ther 2010, 17(4):289-297. 
32. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L: 
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic 
adenoviruses. Mol Cancer Thera 2006, 5(3):755-766. 
33. Xiang J, Tang J, Song C, Yang Z, Hirst DG, Zheng QJ, Li G: 
Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. 
Cytotherapy 2009, 11(5):516-526. 
34. Loebinger MR, Eddaoudi A, Davies D, Janes SM: Mesenchymal stem 
cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009, 
69(10):4134-4142. 
35. Klein JD, Turner CG, Steigman SA, Ahmed A, Zurakowski D, Eriksson 
E, Fauza DO: Amniotic mesenchymal stem cells enhance normal fetal wound 
healing. Stem Cells Dev 2011, 20(6):969-976. 
36. Luo G, Cheng W, He W, Wang X, Tan J, Fitzgerald M, Li X, Wu J: 
Promotion of cutaneous wound healing by local application of mesenchymal 
stem cells derived from human umbilical cord blood. Wound Repair Regen 2010, 
18(5):506-513. 
37. Zebardast N, Lickorish D, Davies JE: Human umbilical cord 
perivascular cells (HUCPVC): A mesenchymal cell source for dermal wound 
healing. Organogenesis 2010, 6(4):197-203. 
38. Stolzing A, Scutt A: Age-related impairment of mesenchymal progenitor 
cell function. Aging Cell 2006, 5(3):213-224. 
39. Fan Y, Chong YS, Choolani MA, Cregan MD, Chan JK: Unravelling the 




40. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS: Viable 
offspring derived from fetal and adult mammalian cells. Nature 1997, 
385(6619):810-813. 
41. Park I-H, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, 
Lensch MW, Daley GQ: Reprogramming of human somatic cells to 
pluripotency with defined factors. Nature 2008, 451(7175):141-146. 
42. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from 
mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 
126(4):663-676. 
43. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa 
M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka 
S: Variation in the safety of induced pluripotent stem cell lines. Nat Biotech 
2009, 27(8):743-745. 
44. Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, 
Doody M, Venter D, Pain S, Gilshenan K, Atkinson K: Comparison of human 
placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem 
Cells Dev 2008, 17(6):1095-1107. 
45. Wulf GG, Viereck V, Hemmerlein B, Haase D, Vehmeyer K, Pukrop T, 
Glass B, Emons G, Trumper L: Mesengenic progenitor cells derived from 
human placenta. Tissue Eng 2004, 10(7-8):1136-1147. 
46. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-
Swings GM, Claas FH, Fibbe WE, Kanhai HH: Isolation of mesenchymal stem 
cells of fetal or maternal origin from human placenta. Stem Cells 2004, 
22(7):1338-1345. 
47. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M: Oct-
4-expressing cells in human amniotic fluid: A new source for stem cell research? 
Hum Reprod 2003, 18(7):1489-1493. 
48. Tsai MS, Lee JL, Chang YJ, Hwang SM: Isolation of human multipotent 
mesenchymal stem cells from second-trimester amniotic fluid using a novel 
two-stage culture protocol. Hum Reprod 2004, 19(6):1450-1456. 
49. De Coppi P, Bartsch G, Jr., Siddiqui MM, Xu T, Santos CC, Perin L, 
Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A: 




50. Antonucci I, Iezzi I, Morizio E, Mastrangelo F, Pantalone A, Mattioli-
Belmonte M, Gigante A, Salini V, Calabrese G, Tete S, Palka G, Stuppia L: 
Isolation of osteogenic progenitors from human amniotic fluid using a single 
step culture protocol. BMC Biotechnol 2009, 9:9. 
51. Erices A, Conget P, Minguell JJ: Mesenchymal progenitor cells in 
human umbilical cord blood. Br J Haematol 2000, 109(1):235-242. 
52. McGuckin CP, Forraz N, Baradez MO, Navran S, Zhao J, Urban R, 
Tilton R, Denner L: Production of stem cells with embryonic characteristics 
from human umbilical cord blood. Cell Prolif 2005, 38(4):245-255. 
53. Berard X, Remy-Zolghadri M, Bourget C, Turner N, Bareille R, Daculsi 
R, Bordenave L: Capability of human umbilical cord blood progenitor-derived 
endothelial cells to form an efficient lining on a polyester vascular graft in vitro. 
Acta Biomater 2009, 5(4):1147-1157. 
54. Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, Shih YH, Ko 
MH, Sung MS: Conversion of human umbilical cord mesenchymal stem cells in 
Wharton's jelly to dopaminergic neurons in vitro: Potential therapeutic 
application for Parkinsonism. Stem Cells 2006, 24(1):115-124. 
55. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai 
MC, Chen CC: Mesenchymal stem cells in the Wharton's jelly of the human 
umbilical cord. Stem Cells 2004, 22(7):1330-1337. 
56. Seshareddy K, Troyer D, Weiss ML: Method to isolate mesenchymal-
like cells from Wharton's Jelly of umbilical cord. Methods Cell Biol 2008, 
86:101-119. 
57. Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav 
S, Luo Y, Rao MS, Velagaleti G, Troyer D: Human umbilical cord matrix stem 
cells: Preliminary characterization and effect of transplantation in a rodent 
model of Parkinson's disease. Stem Cells 2006, 24(3):781-792. 
58. Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, 
Lanzoni G, Cantoni S, Cavallini C, Bianchi F, Tazzari PL, Pasquinelli G, Foroni 
L, Ventura C, Grossi A, Bagnara GP: Term Amniotic membrane is a high 
throughput source for multipotent mesenchymal stem cells with the ability to 




59. Liu S, Liston RM, Joseph KS, Heaman M, Sauve R, Kramer MS, For the 
Maternal Health Study Group of the Canadian Perinatal Surveillance System: 
Maternal mortality and severe morbidity associated with low-risk planned 
cesarean delivery versus planned vaginal delivery at term. CMAJ 2007, 
176(4):455-460. 
60. Bodner K, Wierrani F, Grünberger W, Bodner-Adler B: Influence of the 
mode of delivery on maternal and neonatal outcomes: A comparison between 
elective cesarean section and planned vaginal delivery in a low-risk obstetric 
population. Arch Gynecol Obstet 2011, 283(6):1193-1198. 
61. Beischer NA, Mackay EV, Colditz P: Obstetrics and The Newborn - An 
Illustrated Textbook. 3rd edition. London: W. B. Saunders Company Ltd; 1997. 
62. Hanretty KP: Obstetrics Illustrated. 6th edition. London: Churchill 
Livingstone; 2003. 
63. Harris DT, Rogers I: Umbilical cord blood: a unique source of 
pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther 2007, 
2(4):301-309. 
64. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, 
Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J: 
Hematopoietic engraftment and survival in adult recipients of umbilical-cord 
blood from unrelated donors. N Engl J Med 2001, 344(24):1815-1822. 
65. Cohena Y, Nagler A: Hematopoietic stem-cell transplantation using 
umbilical-cord blood. Leuk Lymphoma 2003, 44(8):1287-1299. 
66. Hayani A, Lampeter E, Viswanatha D, Morgan D, Salvi SN: First report 
of autologous cord blood transplantation in the treatment of a child with 
leukemia. Pediatrics 2007, 119(1):e296-300. 
67. Perdikogianni C, Dimitriou H, Stiakaki E, Martimianaki G, Kalmanti M: 
Could cord blood be a source of mesenchymal stromal cells for clinical use? 
Cytotherapy 2008, 10(5):452-459. 
68. Bieback K, Kern S, Kluter H, Eichler H: Critical parameters for the 




69. Secco M, Zucconi E, Vieira NM, Fogaca LL, Cerqueira A, Carvalho MD, 
Jazedje T, Okamoto OK, Muotri AR, Zatz M: Multipotent stem cells from 
umbilical cord: Cord is richer than blood! Stem Cells 2008, 26(1):146-150. 
70. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, 
Lu YX, Liu D, Chen ZZ, Han ZC: Isolation and characterization of human 
umbilical cord mesenchymal stem cells with hematopoiesis-supportive function 
and other potentials. Haematologica 2006, 91(8):1017-1026. 
71. Reza H, Ng B-Y, Phan T, Tan D, Beuerman R, Ang L: Characterization 
of a novel umbilical cord lining cell with CD227 positivity and unique pattern of 
P63 expression and function. Stem Cell Rev 2011, 7(3):624-638. 
72. Baksh D, Yao R, Tuan RS: Comparison of proliferative and multilineage 
differentiation potential of human mesenchymal stem cells derived from 
umbilical cord and bone marrow. Stem Cells 2007, 25(6):1384-1392. 
73. Gotherstrom C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K: 
Difference in gene expression between human fetal liver and adult bone marrow 
mesenchymal stem cells. Haematologica 2005, 90(8):1017-1026. 
74. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz 
MA, Itskovitz-Eldor J, Thomson JA: Clonally derived human embryonic stem 
cell lines maintain pluripotency and proliferative potential for prolonged periods 
of culture. Dev Biol 2000, 227(2):271-278. 
75. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A: Embryonic 
stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat 
Biotechnol 2000, 18(4):399-404. 
76. Zhang X, Stojkovic P, Przyborski S, Cooke M, Armstrong L, Lako M, 
Stojkovic M: Derivation of human embryonic stem cells from developing and 
arrested embryos. Stem Cells 2006, 24(12):2669-2676. 
77. Allegrucci C, Denning C, Priddle H, Young L: Stem-cell consequences 
of embryo epigenetic defects. Lancet 2004, 364(9429):206-208. 
78. Hauner H, Entenmann G: Regional variation of adipose differentiation in 
cultured stromal-vascular cells from the abdominal and femoral adipose tissue 
of obese women. Int J Obes 1991, 15(2):121-126. 
79. Freshney RI: Culture of Animal Cells: A Manual of Basic Technique. 4th 
edition. New York: Wiley-Liss, Inc.; 2000. 
131 
 
80. Lim IJ, Phan TT: Isolation of stem/progenitor cells from amniotic 
membrane of umbilical cord. UK Intellectual Property Office - The Patents & 
Designs Journal 2008, 6189:GB2432166. 
81. Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG: Isolation and 
characterization of mesenchymal stem cells from the sub-amniotic human 
umbilical cord lining membrane. Stem Cells Dev 2010, 19(4):491-502. 
82. Deuse T, Stubbendorff M, Tang-Quan K, Phillips N, Kay MA, Eiermann 
T, Phan TT, Volk HD, Reichenspurner H, Robbins RC, Schrepfer S: 
Immunogenicity and immunomodulatory properties of umbilical cord lining 
mesenchymal stem cells. Cell Transplant 2011, 20(5):655-667. 
83. Zhou Y, Gan SU, Lin G, Lim YT, Masilamani J, Mustafa FB, Phua ML, 
Rivino L, Phan TT, Lee KO, Calne R, Macary PA: Characterization of human 
umbilical cord lining derived epithelial cells and transplantation potential. Cell 
Transplant 2011, In press(DOI: 10.3727/096368910x564085). 
84. Carosella ED, Dausset J, Rouas-Freiss N: Immunotolerant functions of 
HLA-G. Cell Mol Life Sci 1999, 55(3):327-333. 
85. LeMaoult J, Rouas-Freiss N, Carosella ED: Immuno-tolerogenic 
functions of HLA-G: Relevance in transplantation and oncology. Autoimmun 
Rev 2005, 4(8):503-509. 
86. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, 
Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 
2001. JAMA 2003, 289(1):76-79. 
87. Lightwood J, Bibbins-Domingo K, Coxson P, Wang YC, Williams L, 
Goldman L: Forecasting the future economic burden of current adolescent 
overweight: An estimate of the coronary heart disease policy model. Am J 
Public Health 2009, 99(12):2230-2237. 
88. Huang ES, Basu A, O'Grady M, Capretta JC: Projecting the future 
diabetes population size and related costs for the U.S. Diabetes Care 2009, 
32(12):2225-2229. 
89. Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL: 




90. Colagiuri S, Lee CM, Colagiuri R, Magliano D, Shaw JE, Zimmet PZ, 
Caterson ID: The cost of overweight and obesity in Australia. Med J Aust 2010, 
192(5):260-264. 
91. Tsai AG, Williamson DF, Glick HA: Direct medical cost of overweight 
and obesity in the USA: A quantitative systematic review. Obes Rev 2011, 
12(1):50-61. 
92. Disease Burden. In Statistics - Health Facts Singapore 2007, accessed 
18 Feb 2011. Singapore: Ministry of Health, Singapore, 
(http://www.moh.gov.sg/mohcorp/statistics.aspx?id=23712). 
93. Gregoire FM, Smas CM, Sul HS: Understanding adipocyte 
differentiation. Physiol Rev 1998, 78(3):783-809. 
94. Fruhbeck G: Overview of adipose tissue and its role in obesity and 
metabolic disorders. Methods Mol Biol 2008, 456:1-22. 
95. Gurevich-Panigrahi T, Panigrahi S, Wiechec E, Los M: Obesity: 
Pathophysiology and clinical management. Curr Med Chem 2009, 16(4):506-
521. 
96. Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, 
Cianflone K: Plasma acylation stimulating protein, adipsin and lipids in non-
obese and obese populations. Eur J Clin Invest 1999, 29(8):679-686. 
97. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP: 
Effect of body weight and caloric restriction on serum complement proteins, 
including Factor D/adipsin: Studies in anorexia nervosa and obesity. Clin Exp 
Immunol 1997, 108(3):507-515. 
98. Hung SC, Chang CF, Ma HL, Chen TH, Low-Tone Ho L: Gene 
expression profiles of early adipogenesis in human mesenchymal stem cells. 
Gene 2004, 340(1):141-150. 
99. Nakamura T, Shiojima S, Hirai Y, Iwama T, Tsuruzoe N, Hirasawa A, 
Katsuma S, Tsujimoto G: Temporal gene expression changes during 
adipogenesis in human mesenchymal stem cells. Biochem Biophys Res Commun 
2003, 303(1):306-312. 
100. Stahl A, Evans JG, Pattel S, Hirsch D, Lodish HF: Insulin causes fatty 
acid transport protein translocation and enhanced fatty acid uptake in adipocytes. 
Dev Cell 2002, 2(4):477-488. 
133 
 
101. Hausman GJ: The influence of dexamethasone and insulin on expression 
of CCAAT/enhancer binding protein isoforms during preadipocyte 
differentiation in porcine stromal-vascular cell cultures: Evidence for very early 
expression of C/EBP alpha. J Anim Sci 2000, 78(5):1227-1235. 
102. Suryawan A, Swanson LV, Hu CY: Insulin and hydrocortisone, but not 
triiodothyronine, are required for the differentiation of pig preadipocytes in 
primary culture. J Anim Sci 1997, 75(1):105-111. 
103. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS: Insulin-like growth 
factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J 
Biol Chem 1988, 263(19):9402-9408. 
104. Cianflone K, Maslowska M: Differentiation-induced production of ASP 
in human adipocytes. Eur J Clin Invest 1995, 25(11):817-825. 
105. Mutch DM, Rouault C, Keophiphath M, Lacasa D, Clement K: Using 
gene expression to predict the secretome of differentiating human preadipocytes. 
Int J Obes (Lond) 2009, 33(3):354-363. 
106. Janderova L, McNeil M, Murrell AN, Mynatt RL, Smith SR: Human 
mesenchymal stem cells as an in vitro model for human adipogenesis. Obes Res 
2003, 11(1):65-74. 
107. Gregoire FM: Adipocyte differentiation: From fibroblast to endocrine 
cell. Exp Biol Med 2001, 226(11):997-1002. 
108. White RT, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, Flier 
JS, Spiegelman BM: Human adipsin is identical to complement factor D and is 
expressed at high levels in adipose tissue. J Biol Chem 1992, 267(13):9210-
9213. 
109. Johnson PR, Spiegelman B, Rosen B, Turkenkopf I, Ree H, Greenwood 
MR: Reduced adipsin mRNA and circulating adipsin protein are modulated by 
adrenal steroids in obese Zucker rats. Am J Physiol 1990, 259(1 Pt 2):R184-188. 
110. Lowell BB, Napolitano A, Usher P, Dulloo AG, Rosen BS, Spiegelman 
BM, Flier JS: Reduced adipsin expression in murine obesity: Effect of age and 
treatment with the sympathomimetic-thermogenic drug mixture ephedrine and 




111. Kratchmarova I, Kalume DE, Blagoev B, Scherer PE, Podtelejnikov AV, 
Molina H, Bickel PE, Andersen JS, Fernandez MM, Bunkenborg J, Roepstorff P, 
Kristiansen K, Lodish HF, Mann M, Pandey A: A proteomic approach for 
identification of secreted proteins during the differentiation of 3T3-L1 
preadipocytes to adipocytes. Mol Cell Proteomics 2002, 1(3):213-222. 
112. Hu E, Tontonoz P, Spiegelman BM: Transdifferentiation of myoblasts 
by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc 
Natl Acad Sci U S A 1995, 92(21):9856-9860. 
113. Qiao C, Xu W, Zhu W, Hu J, Qian H, Yin Q, Jiang R, Yan Y, Mao F, 
Yang H, Wang X, Chen Y: Human mesenchymal stem cells isolated from the 
umbilical cord. Cell Biol Int 2008, 32(1):8-15. 
114. Reidy SP, Weber J-M: Leptin: An essential regulator of lipid metabolism. 
Comp Biochem Physiol A Mol Integr Physiol 2000, 125(3):285-298. 
115. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, 
Garvey WT: The metabolic significance of leptin in humans: Gender-based 
differences in relationship to adiposity, insulin sensitivity, and energy 
expenditure. J Clin Endocrinol Metab 1997, 82(4):1293-1300. 
116. Thomas T, Burguera B, Melton LJ, Atkinson EJ, O'Fallon WM, Riggs 
BL, Khosla S: Relationship of serum leptin levels with body composition and 
sex steroid and insulin levels in men and women. Metabolism 2000, 
49(10):1278-1284. 
117. Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat 
and glucose metabolism. Eur J Pharmacol 2002, 440(2-3):213-221. 
118. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, 
Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: Close 
association with insulin resistance and hyperinsulinemia. J Clin Endocrinol 
Metab 2001, 86(5):1930-1935. 
119. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J-i, 
Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, 
Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, 
Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, 




120. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, 
Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum 
immunoreactive-leptin concentrations in normal-weight and obese humans. N 
Engl J Med 1996, 334(5):292-295. 
121. Matsubara M, Maruoka S, Katayose S: Inverse relationship between 
plasma adiponectin and leptin concentrations in normal-weight and obese 
women. Eur J Endocrinol 2002, 147(2):173-180. 
122. Korner A, Wabitsch M, Seidel B, Fischer-Posovszky P, Berthold A, 
Stumvoll M, Bluher M, Kratzsch J, Kiess W: Adiponectin expression in humans 
is dependent on differentiation of adipocytes and down-regulated by humoral 
serum components of high molecular weight. Biochem Biophys Res Commun 
2005, 337(2):540-550. 
123. Jequier E: Leptin signaling, adiposity, and energy balance. Ann N Y Acad 
Sci 2002, 967:379-388. 
124. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM: Leptin enters 
the brain by a saturable system independent of insulin. Peptides 1996, 
17(2):305-311. 
125. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, 
Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV: Decreased 
cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for 
leptin resistance. Lancet 1996, 348(9021):159-161. 
126. Ross MH, Pawlina W: Histology: A text and atlas. 5th edition. Baltimore, 
MD: Lippincott Williams & Wilkins; 2006. 
127. Action Plan for Liver Disease Research. In A Report of the Liver Disease 
Subcommittee of the Digestive Diseases Interagency Coordinating Committee. 
Bethesda, Maryland: National Institute of Health, US 2009. 
128. McKenzie TJ, Lillegard JB, Nyberg SL: Artificial and bioartificial liver 
support. Semin Liver Dis 2008, 28(2):210-217. 
129. Pless G: Bioartificial liver support systems. Methods Mol Biol 2010, 
640:511-523. 
130. Hashimoto M, Watanabe G: Functional restoration of cirrhotic liver after 
partial hepatectomy in the rat. Hepatogastroenterology 2005, 52(63):897-902. 
136 
 
131. Elchaninov AV, Bolshakova GB: Reparative regeneration of rat fetal 
liver after partial hepatectomy. Bull Exp Biol Med 2011, 150(3):383-386. 
132. Si-Tayeb K, Lemaigre FP, Duncan SA: Organogenesis and development 
of the liver. Dev Cell 2010, 18(2):175-189. 
133. Sadler TW: Langman's Medical Embryology. 11th edition. Twin Bridges, 
Montana: Lippincott Williams & Wilkins; 2010. 
134. Duncan SA: Mechanisms controlling early development of the liver. 
Mech Dev 2003, 120(1):19-33. 
135. Li J, Ning G, Duncan SA: Mammalian hepatocyte differentiation 
requires the transcription factor HNF-4 alpha. Genes Dev 2000, 14(4):464-474. 
136. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, 
Kaestner KH, Rossi JM, Zaret KS, Duncan SA: Hepatocyte nuclear factor 
4alpha controls the development of a hepatic epithelium and liver 
morphogenesis. Nat Genet 2003, 34(3):292-296. 
137. Reiser J, Zhang XY, Hemenway CS, Mondal D, Pradhan L, La Russa 
VF: Potential of mesenchymal stem cells in gene therapy approaches for 
inherited and acquired diseases. Expert Opin Biol Ther 2005, 5(12):1571-1584. 
138. Campard D, Lysy PA, Najimi M, Sokal EM: Native umbilical cord 
matrix stem cells express hepatic markers and differentiate into hepatocyte-like 
cells. Gastroenterology 2008, 134(3):833-848. 
139. Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen 
JR, Chen YP, Lee OK: In vitro hepatic differentiation of human mesenchymal 
stem cells. Hepatology 2004, 40(6):1275-1284. 
140. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, 
Lenvik T, Johnson S, Hu WS, Verfaillie CM: Multipotent adult progenitor cells 
from bone marrow differentiate into functional hepatocyte-like cells. J Clin 
Invest 2002, 109(10):1291-1302. 
141. Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ: 
Hepatocyte cell lines: Their use, scope and limitations in drug metabolism 
studies. Expert Opin Drug Metab Toxicol 2006, 2(2):183-212. 
137 
 
142. Gonzalez FJ, Lee YH: Constitutive expression of hepatic cytochrome 
P450 genes. FASEB J 1996, 10(10):1112-1117. 
143. Delesque-Touchard N, Park SH, Waxman DJ: Synergistic action of 
hepatocyte nuclear factors 3 and 6 on CYP2C12 gene expression and 
suppression by growth hormone-activated STAT5b. Proposed model for female 
specific expression of CYP2C12 in adult rat liver. J Biol Chem 2000, 
275(44):34173-34182. 
144. Xu J, Li Q: Review of the in vivo functions of the p160 steroid receptor 
coactivator family. Mol Endocrinol 2003, 17(9):1681-1692. 
145. Snykers S, De Kock J, Rogiers V, Vanhaecke T: In vitro differentiation 
of embryonic and adult stem cells into hepatocytes: State of the art. Stem Cells 
2009, 27(3):577-605. 
146. Mizuno M, Singer SJ: A soluble secretory protein is first concentrated in 
the endoplasmic reticulum before transfer to the golgi apparatus. Proc Natl Acad 
Sci U S A 1993, 90(12):5732-5736. 
147. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin 
TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW: New 
consensus nomenclature for mammalian keratins. J Cell Biol 2006, 174(2):169-
174. 
148. Bordeleau F, Galarneau L, Gilbert S, Loranger A, Marceau N: Keratin 
8/18 modulation of protein kinase C-mediated integrin-dependent adhesion and 
migration of liver epithelial cells. Mol Biol Cell 2010, 21(10):1698-1713. 
149. Tao GZ, Looi KS, Toivola DM, Strnad P, Zhou Q, Liao J, Wei Y, 
Habtezion A, Omary MB: Keratins modulate the shape and function of 
hepatocyte mitochondria: A mechanism for protection from apoptosis. J Cell Sci 
2009, 122(Pt 21):3851-3855. 
150. Chien C-C, Yen BL, Lee F-K, Lai T-H, Chen Y-C, Chan S-H, Huang H-
I: In vitro differentiation of human placenta-derived multipotent cells into 
hepatocyte-like cells. Stem Cells 2006, 24(7):1759-1768. 
151. Haruna Y, Saito K, Spaulding S, Nalesnik MA, Gerber MA: 
Identification of bipotential progenitor cells in human liver development. 
Hepatology 1996, 23(3):476-481. 
138 
 
152. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ: Cell lines: A tool 
for in vitro drug metabolism studies. Curr Drug Metab 2008, 9(1):1-11. 
153. Dehn PF, White CM, Conners DE, Shipkey G, Cumbo TA: 
Characterization of the human hepatocellular carcinoma (hepg2) cell line as an 
in vitro model for cadmium toxicity studies. In Vitro Cell Dev Biol Anim 2004, 
40(5-6):172-182. 
154. Verma P, Verma V, Ray P, Ray AR: Agar-gelatin hybrid sponge-
induced three-dimensional in vitro 'liver-like' HepG2 spheroids for the 
evaluation of drug cytotoxicity. J Tissue Eng Regen Med 2009, 3(5):368-376. 
155. Rudzok S, Schlink U, Herbarth O, Bauer M: Measuring and modeling of 
binary mixture effects of pharmaceuticals and nickel on cell 
viability/cytotoxicity in the human hepatoma derived cell line HepG2. Toxicol 
Appl Pharmacol 2010, 244(3):336-343. 
156. Lan SF, Safiejko-Mroczka B, Starly B: Long-term cultivation of HepG2 
liver cells encapsulated in alginate hydrogels: A study of cell viability, 
morphology and drug metabolism. Toxicol In Vitro 2010, 24(4):1314-1323. 
157. Jover R, Bort R, Gómez-Lechón MJ, Castell JV: Cytochrome P450 
regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using 
adenovirus-mediated antisense targeting. Hepatology 2001, 33(3):668-675. 
158. Schmelzer E, Wauthier E, Reid LM: The phenotypes of pluripotent 
human hepatic progenitors. Stem Cells 2006, 24(8):1852-1858. 
159. Chivu M, Dima SO, Stancu CI, Dobrea C, Uscatescu V, Necula LG, 
Bleotu C, Tanase C, Albulescu R, Ardeleanu C, Popescu I: In vitro hepatic 
differentiation of human bone marrow mesenchymal stem cells under 
differential exposure to liver-specific factors. Translational Research 2009, 
154(3):122-132. 
160. Lemaigre FP: Mechanisms of liver development: Concepts for 
understanding liver disorders and design of novel therapies. Gastroenterology 
2009, 137(1):62-79. 
161. Tanimizu N, Miyajima A: Molecular mechanism of liver development 
and regeneration. Int Rev Cytol 2007, 259:1-48. 
162. Guguen-Guillouzo C, Guillouzo A: General review on in vitro 
hepatocyte models and their applications. Methods Mol Biol 2010, 640:1-40. 
139 
 
163. Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W, 
Mannens G: Cell-based models to study hepatic drug metabolism and enzyme 
induction in humans. Expert Opin Drug Metab Toxicol 2005, 1(1):75-90. 
164. Asha S, Vidyavathi M: Role of human liver microsomes in in vitro 
metabolism of drugs-A review. Appl Biochem Biotechnol 2010, 160(6):1699-
1722. 
165. Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM: An 
update on in vitro test methods in human hepatic drug biotransformation 
research: Pros and cons. Toxicol Appl Pharmacol 2003, 189(3):233-246. 
166. Raucy JL, Lasker JM: Isolation of P450 enzymes from human liver. 
Methods Enzymol 1991, 206:577-587. 
167. Hashemi E, Till C, Ioannides C: Stability of cytochrome P450 proteins 
in cultured precision-cut rat liver slices. Toxicology 2000, 149(2-3):51-61. 
168. Park J-G, Lee J-H, Kang M-S, Park K-J, Jeon Y-M, Lee H-J, Kwon H-S, 
Park H-S, Yeo K-S, Lee K-U, Kim S-T, Chung J-K, Hwang Y-J, Lee H-S, Kim 
CY, Lee YI, Chen T-R, Hay RJ, Song S-Y, Kim W-H, Kim C-W, Kim Y-I: 
Characterization of cell lines established from human hepatocellular carcinoma. 
Int J Cancer 1995, 62(3):276-282. 
169. Iyer VV, Yang H, Ierapetritou MG, Roth CM: Effects of glucose and 
insulin on HepG2-C3A cell metabolism. Biotechnol Bioeng 2010, 107(2):347-
356. 
170. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, 
Vignaud JM, Juillerat M, Lipsky MM, Trump BF: Simian virus 40 large tumor 
antigen-immortalized normal human liver epithelial cells express hepatocyte 
characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A 
1993, 90(11):5123-5127. 
171. Sumida A, Kinoshita K, Fukuda T, Matsuda H, Yamamoto I, Inaba T, 
Azuma J: Relationship between mRNA levels quantified by reverse 
transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 
in human liver. Biochem Biophys Res Commun 1999, 262(2):499-503. 
172. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, 
Castell JV, Gómez-Lechón M-J: Cytochrome P450 expression in human 
hepatocytes and hepatoma cell lines: Molecular mechanisms that determine 
lower expression in cultured cells. Xenobiotica 2002, 32(6):505-520. 
140 
 
173. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: 
Interindividual variations in human liver cytochrome P-450 enzymes involved 
in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver 
microsomes of 30 japanese and 30 caucasians. J Pharmacol Exp Ther 1994, 
270(1):414-423. 
174. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R: Human 
hepatocytes in primary culture: The choice to investigate drug metabolism in 
man. Curr Drug Metab 2004, 5(5):443-462. 
175. Wang G, Hsieh Y, Cui X, Cheng KC, Korfmacher WA: Ultra-
performance liquid chromatography/tandem mass spectrometric determination 
of testosterone and its metabolites in in vitro samples. Rapid Commun Mass 
Spectrom 2006, 20(14):2215-2221. 
176. Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, Waring 
JF: Gene expression in human hepatocytes in suspension after isolation is 
similar to the liver of origin, is not affected by hepatocyte cold storage and 
cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab 
Dispos 2006, 34(5):870-879. 
177. Dunn JC, Tompkins RG, Yarmush ML: Long-term in vitro function of 
adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 1991, 
7(3):237-245. 
178. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, 
Brouwer KL: P-glycoprotein expression, localization, and function in sandwich-
cultured primary rat and human hepatocytes: Relevance to the hepatobiliary 
disposition of a model opioid peptide. Pharm Res 2004, 21(7):1294-1302. 
179. Li J, Tao R, Wu W, Cao H, Xin J, Guo J, Jiang L, Gao C, Demetriou AA, 
Farkas DL, Li L: 3D PLGA scaffolds improve differentiation and function of 
bone marrow mesenchymal stem cell-derived hepatocytes. Stem Cells Dev 2010, 
19(9):1427-1436. 
180. Baharvand H, Hashemi SM, Kazemi Ashtiani S, Farrokhi A: 
Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D 
culture systems in vitro. Int J Dev Biol 2006, 50(7):645-652. 
181. Kudryavtseva EI, Engelhardt NV: Requirement of 3D extracellular 
network for maintenance of mature hepatocyte morphology and suppression of 
alpha-fetoprotein synthesis in vitro. Immunol Lett 2003, 90(1):25-31. 
 
